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Summary
Background: Transoesophageal echocardiographic (TOE)-defined mobile, thread-like 
valvular strands (VS) have been associated with acute ischaemic stroke (AIS). The 
relationship between VS as a possible embolic substrate and the risk o f recurrent stroke 
remains unclear. Our primary aims were to measure the prevalence o f VS and explore 
their association with AIS in a case-control study and then, compare the risk of 
subsequent poor vascular outcome (vascular events and vascular death) in the stroke 
cohort patients with or without VS in a follow-up study. Our secondary aims were to 
determine the relationship o f VS to other potential cardiac sources o f emboli in TOE, 
relationship of VS to diastolic dysfunction in stroke cohort on comparison with controls. 
In addition, we sought to evaluate the relationship of VS to ischaemic stroke subtype 
and infarct topography on neuroimaging, and also to determine the relationship of 
hypercoagulable states in young patients with VS in the stroke cohort.
Methods: In the case-control study, the prevalence of VS was estimated from patients 
consecutively admitted with AIS and from patients underwent TOE for cardiac 
conditions (those with infective endocarditis and stroke were excluded) in our 
institution over a two year period. In the follow-up study, patients with AIS were 
followed to evaluate the risk of poor vascular outcome, including risk of recurrent 
stroke.
Results: We recruited 170 patients with AIS and o f those, 78 underwent TOE. In our 
case-control study, we found TOE-defmed VS in approximately half of the patients with 
AIS (38/78, 48.7%) compared to one-third of controls (29/89, 32.6%). VS were more 
commonly seen in stroke patients over the age of 60 years (21/34, 61.8%). Univariate 
analysis found an association between the presence of VS and risk o f AIS (OR = 3.85 ,p  
= 0.05), but multivariate analysis reduced the strength of the association (OR = 2.15,p
= 0.06). In stroke subtypes, high prevalence of VS was seen in cardioembolic stroke but 
it did not reach statistical significance (p = 0.52) and there was no increased frequency 
of VS in cryptogenic stroke subtype. Diastolic dysfunction was seen in 78.9 % of cases 
with VS and there was a strong association between diastolic dysfunction and VS in the 
case-control study (OR 7.75,/) = 0.005). There was no statistically significant 
association between infarct location (cortical, subcortical, brainstem or cerebellar) in 
neuroimaging and the presence o f VS. There were only few young cases with 
abnormalities in laboratory testing for hypercoagulable conditions. The risk of recurrent 
stroke and survival without poor vascular outcome was not statistically different 
between cases with or without VS in our study (OR = 1.45, 95 % Cl 0.30 - 6.96 ,p  = 
0.64).
Conclusion: We were able to demonstrate an association between valvular strands and 
acute ischaemic stroke in our case-control study, however, the strength of the 
association was reduced after multivariate analysis. We did not find any increased risk 
of poor vascular outcome or increased recurrent stroke risk in cases with or without VS. 
Our findings do not support the embolic potential o f valvular strands and it may not be a 
risk factor for stroke.
9
Chapter 1: Introduction
1.1 Acute ischaemic stroke and pathophysiology
Acute ischaemic stroke (AIS) is characterized by abrupt neurologic dysfunction 
due to focal brain ischaemia resulting in persistent neurologic deficit or 
accompanied by characteristic abnormalities on brain imaging (1). History and 
findings of physical examination facilitate stroke diagnosis. The NIH Stroke 
Scale (NIHSS) is a validated 15-item scale that is used to assess key components 
of the standard neurologic examination and measure stroke severity (2). 
Noncontrast head CT is most readily available in most stroke centres and may 
be rapidly performed as part of the acute stroke evaluation. MRI with diffusion- 
weighted imaging sequences is more sensitive for acute cerebral ischaemia and 
improves diagnostic accuracy (3).
A minimal diagnostic evaluation of stroke includes the following (4):
(a) Assessment of main risk factors: Hypertension, hypercholesterolemia, 
diabetes, cardiac disease, family history o f vascular disease
(b) Laboratory testing for haematocrit, platelets, red and white cell counts 
and prothrombin time
(c) Electrocardiogram
(d) Assessment of extra and intracranial arteries
(e) Assessment for specific etiologies
Thromboembolism and hacmodynamic failure are the two major mechanisms 
for AIS. Thromboembolism usually occurs as a result of embolism or in situ
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thrombosis and leads to an abrupt fall in regional blood supply. The most 
common sources of embolism are heart and large arteries. Cardioembolism 
accounts for 20 -  30 % of all ischaemic strokes (5-8). The extension o f the 
infarct on CT and MRI can provide important information towards a cardiogenic 
embolic stroke mechanism. It is very likely to be cardioembolic mechanism if 
the neuroimaging shows a cortical extension, multiplicity in space and time, or 
bilaterality (9). There is also a specific type o f subcortical infact, the large 
‘lenticulostriate infarct’ which typically indicate embolic stroke mechanism 
(10). Other signs of systemic thromboembolism such as wedge shaped 
infarctions of kidney or spleen, Osier nodes could also help to identify a 
cardioembolic mechanism (11).
Identification of a cardiac source of embolism in patients with transient 
ischaemic stroke (TIA) or AIS is important because it influences future 
therapeutic management. Conditions considered at high risk for cardioembolism 
include atrial fibrillation, sick sinus syndrome, intracardiac thrombus, left atrial 
myxoma, mitral stenosis, prosthetic valve, infective endocarditis, recent 
myocardial infarction, dilated cardiomyopathy, and aortic arch atheromatous 
plaques. Conditions considered at low or uncertain risk for brain embolization 
include patent foramen ovale, atrial septal aneurysm, spontaneous echo contrast, 
mitral annulus calcification, mitral valve prolapse, calcified aortic stenosis, 
Lambl excrescences (valvular strands), and dyskinetic ventricular wall segment 
(11-13).
Cardiac evaluation to identify the risk factors for embolization include telemetry 
or holter monitoring, transthoracic echocardiography (TTE), transoesopahageal 
echocardiography (TOE), coronary angiography and cardiac CT or MRI based
on history and clinical examination. TOE has revolutionized the search for 
cardiac sources of embolism due to its non-invasive nature, relatively good 
sensitivity and high specificity (14). TOE is particularly valuable in indentifying 
aortic atheromas, valvular vegetations and masses, left atrial thrombi, 
spontaneous echo contrast and inter-atrial shunts. In current clinical practice, 
echocardiography is used in over 80% of patients with acute stroke as a major 
cornerstone in diagnostic work-up with a 1:3 ratio of TTE alone vs. TOE (11).
With this increasingly routine use of TOE in the evaluation of AIS, VS are 
increasingly detected on cardiac valves. VS have been implicated in systemic 
embolization (15) and are considered as a risk factor for stroke in young patients 
(16). It was postulated that VS may themselves break and embolize, or thrombi 
formed on the surface due to endothelial damage or local trauma subsequently 
embolize causing stroke (17, 18). Thrombi on giant Lambl excrescences have 
been previously reported (19). An independent association was identified 
between mitral VS and ischaemic stroke in elderly (20) however, there are no 
prospective studies to explore the relationship o f stroke with VS in all age 
groups. There is also a lack o f increased risk of recurrent stroke (20) and thus it 
raises doubts about the possible etiological role o f VS in AIS.
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1.2 Definition of valvular strands
Valvular strands are thin, mobile, thread-like filaments seen on the edges of 
cardiac valves (21, 22). Vilem Dusan Lambl, a Czech physician first described 
small filiform processes on the ventricular surface o f aortic valve leaflets (21) in 
1856. He identified such processes in 2% of 1000 autopsies performed. 
Subsequently, Magarey reported the presence of similar filiform excrescences 
on the auricular surface of mitral valves in 85% of an autopsy series o f 250 
patients (22). Generally, these excrescences were found to be less than 1 mm 
thick and 1 tolO mm long. These strands were subsequently named ‘Lambl’s 
excrescences’ (LE). With the widespread use of sophisticated cardiac imaging 
modalities, abnormal structures attached to cardiac valves are frequent findings 
on cardiac investigations (23). In 1990, Lee et al. (24) described strands on the 
mitral valves identified in TOE, which are pathologically LEs when examined. 
These were subsequently termed ‘valvular strands’ (VS). Increasingly, VS are 
found on TOE, a new window to increase the diagnostic yield of detecting 
intracardiac abnormalities (24).
There is no consensus on the correct terminology for these valvular 
excrescences. Review of literature shows that nomenclature has varied widely 
and these valve structures have been sometimes referred to as papillomas, 
papillary fibromas, endocardial tumours and giant Lambl’s excrescences 
depending on pathological features observed by different authors. LE is 
primarily a histological and VS is an echocardiographic description o f these 
valvular excrescences and therefore we have used the term ‘valvular strands’
13
(VS) to denote the above mentioned structures in TOE studies and ‘Larnbl 
excrescences (LE) in pathological studies. Moreover, therapeutic approaches in 
patients with VS are based on the presence or absence of such structures and 
other risk factors for stroke, without being influenced by histopathologically 
derived terminologies (25).
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There are limited data on the true prevalence and incidence of VS in the general 
population. Early reports by Lambl and Magarey were based on post-mortem 
examinations and no specific pathological significance was attributed to their 
presence. In 1986, Hurle (26) found LEs in 90% of aortic valves among 56 
human subjects (without cardiac disease) examined pathologically. He also 
noted that the frequency of these excrescences were significantly lower in the 
first decade of life.
In 1991, Lee et al. (24) was first to note mitral VS in 22% (11/50) of 
consecutive patients with AIS or TIA undergoing TOE. Few studies have been 
conducted on the subject o f TOE- defined VS and stroke since. The participants 
were selected from patients referred for TOE in the majority of the studies (15, 
16, 27-30). Cohen et al. (20) and Homma et al. (31) recruited from patients who 
had a clinical stroke event. Estimated prevalence of VS in the group o f patients 
with AIS, TIA or with embolic events ranges from 6.3% to 47% and the 
variation in prevalence is perhaps due to difference in the study population. In 
patients without stroke/TIA, the frequency of VS ranges from 0.3% to 38%.
Figure 1.1 and Figure 1.2 show transoesophageal echocardiographic images of 
VS at aortic valve. The prevalence of VS from previous studies are described in 
Table 1.1
1.3 Epidemiology and prevalence of valvular strands
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Figure 1.1: Transoesophageal echocardiographic image o f thin threadlike, valvular strand (red arrow) attached to at the aortic surface of aortic valve. LA left 
atrium, LVleft ventricle, AVaortic valve, Ao aorta, RVOTright ventricular outflow tract.
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Figure 1 .2 : Transoesophageal echocardiographic image aortic valvular strand (red circle) with independent motion to the aortic valve leaflets. LA left atrium, LV 
left ventricle, A V aortic valve, Ao aorta, R VOT right ventricular outflow tract.
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Table 1.1: Prevalence of valvular strands from previous studies
Author/s Cases (identified from TOE 
laboratory) underwent TOE for
Prevalence of 
VS in cases
Controls (identified from TOE 
laboratory) underwent TOE for
Prevalence of 
VS in controls
Statistical
Significance
Freedberg et 
al. (15)
Embolic events 10.6% (63/597) All indications excluding 
cardioembolic events
2.3%(23/962) OR = 4.8, 
P =  0.0001
Tice et al. (16) Ischaemic stroke 6.3% (20/318) All indications excluding stroke 0.3% (2/650) P  = <0.00001)
Roberts et al. 
(27)
Ischaemic stroke or TIA 47% (34/73) All indications excluding stroke, 
TIA, IE, valvular prosthesis, 
peripheral embolism, congenital 
heart defect
16% (12/73) OR = 4.4
Cohen et al. 
(20)
**Patients >60 yrs with 
ischaemic stroke
22.5% (64/284) All indications excluding stroke and 
peripheral embolism
12.1%
(31/256)
OR 2.1,
P = <0.005
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Author/s Cases (identified from TOE 
laboratory) underwent TOE for
Prevalence of 
VS in cases
Controls (identified from TOE 
laboratory) underwent TOE for
Prevalence of 
VS in controls
Statistical
Significance
Menzel et al. 
(28)
Embolic events 46% All indications excluding stroke, IE 
and severe calcification of aortic 
cusps or AV ring
34% P =  0.09
Roldan et al. 
(29)
Patients <60 yrs with ischaemic 
stroke, TIA and peripheral 
embolism (group I)
41% (20/49) Group II- All indications excluding 
cardioembolic events, IE and 
prosthetic valves (n = 88). Group Ill- 
consisted normal subjects (n= 90).
47% (41/88) 
(In normal 
subjects- 38%; 
34/90)
P  <0.001 
overall as well 
as between III 
& I; III & II
Nighoghossian 
et al. (30)
Ischaemic stroke 18.8% (30/160) Cardiac disease (excluding IE, 
valvular prosthesis, peripheral 
embolism, congenital heart defect)
2.2% (4/180) P =  0.001
Homma et al. 
(31)
** Ischaemic stroke 39.4%
(244/619)
Nil NA NA
** These cases were identified prospectively from patients admitted with acute stroke and not from patients underwent TOE for different indications in a TOE laboratory
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1.4 Location and distribution of valvular strands
VS have been reported numerous times involving both native (24) and prosthetic
valves (32, 33).
1.4.1 Native valves
Initial autopsy series by Lambl (21) described LE on aortic valves and 
subsequently on mitral valves by Magarey (22). In 1985, Loire (34) 
analysed 30 consecutive cases to define the anatomy of these LE both 
macroscopically and histologically. The majority of LE was found on 
aortic valves with mitral valve location being the next most frequent. He 
also found LE on both tricuspid and pulmonary valves. Riddle et al. (35) 
performed scanning electron microscopy on 23 diseased mitral valve 
leaflets obtained at the time of prosthetic valve insertion. These were 
from patients over 45 years o f age with probable rheumatic heart disease 
and LEs were seen on 15 of 23 (65%) of these leaflets.
Similarly, TOE studies showed presence o f VS predominantly on left­
sided cardiac valves and some studies were focused predominantly on 
the mitral valve as MV is the most common location for VS. The 
frequency of VS on mitral valves ranges from 6.3% to 76% and on aortic 
valves from 27% to 50% (Table 1.2). This wide range can be explained 
by different groups of patients studied over different age groups. VS 
have been only rarely reported on either tricuspid or pulmonary valves 
(36).
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Table 1.2: Frequency of VS on different cardiac valves derived from previous 
studies
The number of patients with VS in each location/ total number of patients with VS are described 
in parentheses.
Author/s Frequency of VS in cases from previous studies
mitral aortic left-sided * right-sided
Freedberg et al. 70% (60/86) 27% (23/86) 3% (3/86) 0
Roberts et al. 61.8% (21/34) 23.5% (8/34) 14.7% (5/34) 0
Roldan et al. 50% (10/20) 25% (5/20) 25% (5/20) 0
Nighoghossian et 
al.
53.3% (16/30) 20% (6/30) 26.7% (8/30) 0
Lee et al. 22% (11/50)
Tice et al. 6.3% (20/318)
Cohen et al. 22.5% (64/284)
Menzel et al. 39% (86/218)
* combined mitral and aortic VS
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1.4.2 Prosthetic valves
VS on prosthetic valves are frequently detected by TOE and are more 
commonly detected in patients being evaluated for a suspected 
cardioembolic event and thus represent a potential cardiac source of 
embolism (33). Orsinelli et al. (33) identified prosthetic VS in TOE 
studies performed during a 5- year period for evaluation of valve 
dysfunction or a suspected cardioembolic event in patients with valve 
prosthesis. Strands were detected in 56 of 214 (26%) studies. There was 
a significant difference (p = 0.0001) in the prevalence of strands between 
studies performed for a suspected cardioembolic event (34/64; 53%) 
versus those performed for suspected valve dysfunction (22/150; 15%). 
VS were more prevalent on mitral than on aortic valves (32% vs. 13%, p  
= 0.0004) and were more frequently detected on mechanical rather than 
on bioprosthetic valves (27% vs. 8% ,p = 0.003).
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papillary fibroelastomas. In 1991, Lee et al. (24) reported that gross 
inspection of a mitral valve removed during a mitral valve replacement 
and with documented VS by TOE revealed the strands to be consistent 
with Lambl’s excrescences pathologically.
1.5.2 Echocardiographic differential diagnosis (23)
(a) Thrombi: They are very frequently detected on TOEs. They 
appear as well demarcated, round masses attached to the valves. 
They are not connected to the valves through a stalk, which is an 
important diagnostic feature. Their echodcnsity is usually 
homogenous and difficult to distinguish from cardiac tumours.
(b) Vegetations: Vegetations are large, highly mobile, irregular 
structures attached to the valves and might prolapse through the 
valve and usually associated with significant regurgitation due to 
disruption of normal valvular structure. However, the diagnosis 
needs to be made in the context of an infective clinical picture.
(c) Myxomas: They can occur on cardiac valves, but are attached to 
atrial endocardium through a distinct stalk or pedicle and usually 
contain small areas o f haemorrhage and calcification giving rise 
to irregularities in echodensity. They can be quite large and 
usually associated with valvular stenosis or regurgitation.
(d) Fibroelastomas: Larger lesions are often called cardiac papillary 
fibroelastomas and these are present on valves, away from 
valvular lines of closure, and also on the endocardial surfaces of 
the atria and ventricles. Although LEs and fibroelastomas are
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histologically very similar (40) and a shared pathogenesis has 
been suggested (41), they differ in size and shape. LEs are 
usually long, filiform structures, with a mean size of 8x1 mm and 
commonly appear as strands on TOE. Fibroelastomas are bulky 
with a mean size of 12x9 mm and attached to the valve through a 
stalk or pedicle. Their surface contains multiple small, finger-like 
projections, which appear as fronds on TOE and TTE. These are 
absent in VS. Boone et al. (41) examined hearts with grossly 
classic papillary fibroelastoma and typical Lambl excrescences 
and noted that they are microscopically indistinguishable while 
macroscopically LEs are smaller and broader-based.
(e) Myxomatous degeneration of cardiac valves: It affects the 
structure o f the valve itself rather than structures attached to it. 
Myxomatous degeneration can result in valve thickening with 
protrusions, which are not mobile when examined by TOE.
(f> Soft calcifications: This refers to mobile, heavily calcified 
components involving the valvular annulus and the proximal 
parts of the valves.
(g) Prosthetic sutures: Fibrinised or endothelialised sutures of 
prosthetic valves can be difficult to differentiate; however, they 
are usually thick and placed in a uniform manner.
(h) Cardiac mesothelial/monocytic cardiac excrescences: These 
structures can be found on the cardiac valves, in the atria and in 
the pericardial space during open heart surgery.
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Histologically LEs are composed of acellular connective tissue core 
covered by endothelium (22). Loire reported Lambl’s excrescences in 
two forms (34) when examined macroscopically and histologically: 
mobile, pedunculated either with an acellular fibrous axis containing 
rings of granular eosinophilic material or with more complex 
associations of these changes resulting in pseudo-papillomata of the 
valves. The second form was described as thickening of the valves itself 
and covered by a layer of flattened endothelium.
Among the two types of LEs, lamellar and filiform identified on aortic 
valves by Hurle (26), the connective tissue core of the filiform 
excrescences contained abundant collagen fibrils and elastic material 
arranged in apposed layers with different collagen fibril orientation on 
electron microscopy. At the centre of the filiform excrescences, a circular 
zone devoid of identifiable connective tissue was also described. In 
1989, Riddle et al. (35) studied leaflets obtained from 23 diseased mitral 
valves o f patients over 45 years of age removed at the time of prosthetic 
valve insertion. The clinical diagnosis in all the cases was probable 
rheumatic heart disease and 6 of them had valvuloplasty previously. LEs 
were seen on 65% (15/23) of these leaflets. Electron microscopic 
examination showed that individual LEs varied in size, length and 
external topography. The ends of some LEs were tapered, whereas others 
were rounded and blunt. Occasionally a large projection was further 
divided into several smaller subunits at its base. The exteriors of these
1.5.3 Microscopic description
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processes were either covered with fibres of varying dimensions or a 
cellular layer, presumably o f endothelial cells.
While VS is an echocardiographic description, Lee et al. (24) reported 
that inspection of a mitral valve removed during a mitral valve 
replacement and with documented VS by TOE revealed the VS to be 
consistent with LE pathologically. In 1998, Hutchinson et al. (42) 
confirmed VS on a Medtronic-Hall prosthetic valve in a patient with 
recurrent strokes as LE by histopathological examination.
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Magarey (22) who studied these valvular excrescences at autopsy suggested 
they were more common with advanced age and hypothesized that Lambl’s 
excrescences might be the result of deposition of fibrin over damaged 
endocardial valvular surfaces that became partially detached from the valve, 
condensed and hyalinised and ultimately fibrosed. Fresher fibrin deposits were 
found to be enmeshed with erythrocytes and leucocytes.
Loire (34) suggested several pathogenic mechanisms, all related to local 
conditions rather than to general circulatory changes:
(a) Folding o f the valvular endothelium onto itself followed by organisation into 
tubular structures filled with oedema and hyaline.
(b) Deposits of fibrin layers on zones of endothelial ulceration caused by trauma 
on the line of apposition of the cusps with partial detachment of fibrinous 
material which then endothelialises.
(c) Subendocardial incorporation of oedema, fibrin and red blood cells.
Riddle et al. (35) from the electron microscopic study o f diseased mitral valves 
from probable rheumatic valve disease supported the wear and tear hypothesis 
of formation of LE. At the denuded areas in the valve leaflets, while one end of 
broken bundles of collagen or elastic fibers remained anchored within the 
connective tissue network of the cusp, the free end extended outward from the 
surface of the valve. Platelets were adhered and aggregated to the protruded 
broken bundles or collagen or elastic fibers. Fibrin deposition with subsequent
organisation followed by endothelialisation of the thrombotic deposit covering
1.6 Pathogenesis
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the extended process could explain continuous layering o f the LE by endothelial 
cells in some of them. The wide of range o f sizes observed may be explained by 
variation in the numbers of the fibers initially contained as the core of the 
projection, and accumulation of different amounts of thrombotic material on the 
exterior of the process.
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Autopsy series by Magarey (22) described LE occurring more commonly on 
thickened valves. The initial description of TOE-defined VS by Lee et al. (24), 
also suggested that mitral valve thickening was associated with a higher 
incidence of mitral VS. Subsequently, similar to the findings of Lee et al., a 
higher incidence of thickening of the valves those with VS was reported by 
Cohen et al. (20) and Menzel et al. (28) on mitral and aortic valves respectively. 
Contrary to the previous findings, Freedberg et al. (15) in his study observed 
that VS were common on normal native valves than on valves that were 
significantly thickened. He reported than more than 90% of native valves with 
VS were morphologically normal on TOE. Perhaps, the difference in the 
prevalence of VS could be due to different inclusion criteria used for VS. The 
initial studies by Magarey and Lee et al. included valvular excrescences up to 5 
mm in width while Freedberg at al. excluded excrescences >1 mm in width. In 
addition, Freedberg et al. excluded valves with tom chordae or flail leaflets. Tice 
et al. (16) and Nighoghossian et al. (30), in their TOE studies showed findings 
similar to Freedberg et al. as there was no echocardiographic evidence of higher 
incidence of degenerative valvular changes on valves with VS. Despite to the 
above studies, Roberts et al. (27) described no difference in mitral and aortic 
valve thickness between those with or without VS and thus there is no consensus 
in the literature regarding the nature of valves with VS whether they are 
thickened or normal in nature.
1.7 Relation of valvular strands to valve morphology
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The role of VS can be described as follows:
1.8.1 As a part of normal aging process
Magarey (22) in his study concluded that the appearance of excrescences 
on valves is a part of normal aging process as these were present in all 
individuals older than 60 years. Nighoghossian et al. (30) supported this 
in a follow-up TOE study performed three months after the initial TOEs 
in patients with VS. These strands appeared to remain intact without 
changes in appearance over this period of time.
1.8.2 Obstruction to coronary arteries
In a patient presented with angina pectoris, echocardiographic and 
angiographic examination suggested that the right ostium was obstructed 
by a lesion that was attached to the aortic valve (43). Histopathological 
examination of this lesion after surgical removal confirmed LE. The 
symptoms of patient resolved after the removal o f the same.
1.8.3 Valvular obstruction
Several cases are reported to cause partial occlusion of valves by LE. In a 
report by Thomas et al., a TOE-diagnosed valvular lesion occluding the 
mitral valve was consistent with a giant LE when examined 
histopathologically after its surgical removal (44).
1.8 Role of valvular strands
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1.8.4 As a peripheral embolus
Fitzgerald et al. (45) reported a giant LE presenting as a peripheral 
embolus in a 72 year old man. The embolic material recovered by 
embolectomy was histologically examined and found to be similar to LE.
1.8.5 As a cardiac cause of central embolism (Acute ischaemic stroke/TIA)
In 1991, Lee et al. (24) described TOE-defined VS initially in patients
with recent TIA or stroke of embolic origin and speculated on their role
in cerebral embolism. They postulated that mitral VS may represent a
fissured surface or fibrosis that can serve as a nidus for thrombus
formation. As a mechanism for embolic events, it is possible that either
the strands themselves break and embolize or that the thrombi formed on
the strands which subsequently embolize. Freedberg et al. (15) examined
TOE studies performed in patients with an embolic event (TIA or stroke
or peripheral emboli) and found that 10.6% (63/597)) had VS compared
with only 2.3% (23/962) patients without an embolic event (odds ratio
4.8, 95% confidence interval (Cl) 3.0 to 1.9 ,p  = 0.0001). In other words,
VS were far common in patients with an embolic event. Mitral VS were
found to be significantly more common in patients with a recent
ischaemic cerebrovascular event compared with patients referred for
other indications (6.3% [20/318] versus 0.3% [2/650], respectively; p
<0.00001) for TOE (16). Thirty five percent (7/20) of those with mitral
VS were believed to have had a probable cardioembolic stroke or TIA on
their stroke work-up in this study although it was unable to establish a
cause and effect o f mitral VS and cerebral embolism. Roberts et al. (27)
also confirmed this association between mitral and aortic VS with
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cerebral isehaemia but found no association with the number and length 
of VS with cerebral isehaemia. Similar to previous studies, Cohen et al. 
(20) also found that VS were significantly associated with the risk of 
stroke, but the similar prevalence of VS in patients with a ‘ known cause 
o f  brain infarction ’ and in those ‘without any apparent cause o f  brain 
infarction ’ raised doubts about the potential causal relation with brain 
infarction in patients aged 60 years or older. Roldan et al. (29) sought to 
determine prospectively the evolution and embolic risk of VS in normal 
subjects and patients with and without suspected cardioembolism. In 
subjects with a high prevalence o f VS, the incidence of cerebrovascular 
ischaemic events was low (<0.5 per 100 person-years) and similar to that 
of those without VS. Also, the prevalence o f VS was similar in patients 
with (46%) and without (34%) embolic events. Contrary to the previous 
studies, this study suggested that VS are neither a primary pathogenic 
factor nor a marker for embolism.
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Magarey (22) found that no valves from subjects younger than one year had 
excrescences but that 90% of those between the age 1 to 60 years had 
excrescences. In the TOE studies, Tice et al. (16) reported a relatively higher 
prevalence (16%; 7/44) of mitral VS in young patients (age < 50 years) with 
presumed cardioembolic stroke or TIA. VS were the sole cardiac abnormality in 
9 % of these young patients. Roberts et al. (27) noted more strands in younger 
patients, but this observation did not reach statistical significance. In their study, 
they noted VS were more prevalent in older controls which could be explained 
by the fact that controls were older than the cases. Roldan et al. (29) found that 
prevalence of VS was independent of age groups while Menzel et al. (28) 
reported that VS were increasingly found in older age groups (14% in <40 years, 
32% between >40 but <60 years, 53% in patients > 60 years,/? = 0.001). Thus 
the true prevalence of VS and their association with different age groups of 
patients remains unclear.
1.9 Valvular strands and age
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Stroke subtyping of patients with VS and ischaemic stroke has not been 
uniform in the previous studies reviewing this aspect. The literature is as 
follows:
(a) Tice et al. (16) subtyped patients with VS into three categories: likely 
cardioembolic strokes or TIA (35%; 7/20); unlikely cardioembolic 
stroke which included large vessel atherosclerosis, lacunar, 
fibromuscular dysplasia, migraine and others (50%; 10/120); and 
stroke with uncertain aetiology or incomplete work-up (15%; 3/20).
If we categorize this whole cohort into two groups such as stroke with 
uncertain cause (cryptogenic) and with a known cause of stroke (non- 
cryptogenic), 15% of patients with VS were in the cryptogenic group 
while 85% were in the group of patients with non-cryptogenic stroke.
(b) Roberts et al. (27) classified patients by criteria adapted from the 
Stroke Data Bank (46). He identified VS in 50 % (15/30) of 
cryptogenic, 42% (8/19) of atherothrombotic, 62% (5/8) o f lacunar, 
27% (3/11) cardioembolic strokes and in 60% (3/5) TIA cases. 
Overall, strands were not significantly more frequent in cryptogenic 
stroke patients than in non- cryptogenic stroke patients (50% versus 
42%), but the sample size of the study was small.
(c) Based on cause of stroke, Cohen et al. (20) found that VS were 
present in 24.4% (22/90) patients ‘with a likely cause o f stroke’, 
23.1% (12/52) patients ‘with a possible cause of stroke’, 21.6%
1.10 Valvular strands and stroke subtype
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(11/51) patients with a ‘lacunar infarct’ and in 20.9% (19/91) patients 
‘with no other apparent cause of stroke’. A similar prevalence of VS 
was found in patients ‘with a likely cause o f brain infarction and in 
those ‘without any detectable cause’.
(d) Roldan et al. (29) reported similar prevalence among patients with 
cardioembolic stroke (25%; 5/20), in cardiac and vasculoembolic 
(presence of carotid or aortic atheromatous vessel disease) (35%; 
7/20), vasculoembolic (15%; 3/20) and in nonembolic stroke (25%; 
5/20). There were no patients with VS in the group o f stroke of 
undetermined aetiology.
(c) Homma et al. (31) reported VS in 38.6% (101/262) o f patients with 
cryptogenic stroke compared to 40.1% (143/357) of patients with 
known cause o f stroke and the difference was not statistically 
significant.
Overall, the prevalence o f VS in patients with cryptogenic stroke and in non- 
cryptogenic stroke was not found to be significantly different.
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Although no previous studies reviewed infarct topography in stroke 
patients with VS, it is known that cardioembolic infarcts are generally 
multiple and bilateral. These infarcts are often large and wedge shaped 
although smaller infarcts are also identified. Jung et al. (47) described 
heterogeneous radiologic characteristics of infarcts depending on the risk 
of cardioembolism. Large single territorial infarcts are common in high 
risk cardioembolic group. There are uncertainties about incidence of 
lacunar infarction or small cortico-medullary junction infarction due to 
cardioembolism (48). A recent study by Cho et al. (49) showed that 
patients with cardioembolic sources more frequently had unrecognized 
cerebral infarcts particularly lacunar infarcts than those without; (21/36; 
58.3% versus 57/167; 34.1 % ,p  = 0.008).
1.11 Valvular strands and infarct topography
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1.12 Valvular strands and hyper coagulable state
Hypercoagulable states such as inherited thrombophilias (eg, protein C, 
protein S, or antithrombin III deficiency; factor V leiden; or the 
prothrombin G20210A mutation) and methylenetetrahydrofolate reductase 
(MTHFR) C677T mutation rarely contribute to adult stroke (50). Activated 
protein C (APC) resistance, the most prevalent inherited coagulation 
disorder has been linked to ischaemic stroke in case reports (51). 
Antiphospholipid (APL) antibodies are associated with increased 
thrombogenesis (52, 53) and can cause stroke. The association of APL 
antibodies and stroke is strongest for young adults (< 50 years o f age).
Saidi et al. (54) in their study demonstrated that the presence of lupus 
anticoagulant, and elevated anticardiolipin IgG antibody and 
antiphosphatidylserine antibodies are risk factors for ischaemic stroke. 
Topcuoglu et al. (55) have suggested that in the acute period of ischaemic 
stroke secondary to lone atrial fibrillation, enhancement of the coagulatory 
activity occurs as a result of increased thrombin generation, similar to other 
possible sources of cardioembolism.
A thrombotic origin of valvular strands has been hypothesized in few of 
the prior studies (15, 24, 56). VS may represent a fissured surface or 
fibrosis that can serve as a nidus for thrombus formation. It is possible that 
either the strands themselves break and embolize or thrombi from the 
strands subsequently embolize causing stroke. The observation of VS 
developing in serial TOEs during the resolution of prosthetic MV 
thrombus suggested that VS are composed of platelet-fibrin material (56).
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Roldan et al. (29) tested this thrombotic hypothesis of VS in a population 
with a high prevalence o f antibodies (i.e., patients with connective tissue 
diseases. The presence or concentration of antiphospholipid antibodies was 
not associated with the presence o f VS (29).
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1.13 Valvular strands and risk of recurrent stroke
There are case reports of recurrent strokes in two patients treated on 
anticoagulation for giant LE after their first stroke (19). Two previous 
studies have addressed the risk of recurrent strokes in patients with VS.
Cohen et al. (20) in their study of 284 consecutive patients admitted with 
brain infarction followed the case subjects over a two to four year period 
and the risk of recurrence of brain infarction was estimated in patients with 
and without mitral valvular strands. During 646 per 100 person-years of 
follow-up, the incidence of recurrent brain infarction was 6.0 person-years 
in patients with strands and 4.2 in those without. In the Cox analysis, 
including potential confounders and post-stroke treatment, mitral valve 
strands did not appear as an independent predictor o f recurrent brain 
infarction.
PICSS study showed that in medically treated stroke patients (aspirin or 
warfarin) the presence of valvular strands did not increase the chance of 
adverse events (31).
In a study performed by Nighoghossian et al., strands were not found in 
15.4% of patients on repeat TOE at three months, but there was no clinical 
follow-up to detect any recurrent strokes or TIA (30).
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1.14 Prosthetic valve strands
Orsinelli et al. in 1995 reviewed all TOEs performed during a 5-year period 
for evaluation of valve dysfunction or a suspected cardioembolic event in 
patients with a valve prosthesis (33). VS were detected in 26% (56/214) of 
studies. There was a significant difference (p =0.0001) in the prevalence of 
VS between TOE studies performed for a suspected cardioembolic event 
(53%; 34/64) versus those performed for suspected valve dysfunction (15%; 
22/150). Strands were found more prevalent on mitral valves and more 
frequently detected on mechanical than bioprosthetic valves (27% vs. 8%, p  
= 0.003). They concluded that prosthetic valve strands were frequently 
detected on TOE and were more common in patients being evaluated for a 
suspected cardioembolic event and thus represent a potential cardiac source 
of embolism.
Robert et al. in 1996 performed a late follow-up study in patients with mitral 
mechanical prosthesis and noted the prevalence o f previous embolic events 
was significantly higher in the group with VS than the control group (57). 
The group of patients with VS also contained more patients with a prior 
history of prosthesis thrombosis; however, long-term follow-up was 
uneventful.
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Although valvular strands are detected by TOE, the identification and 
diagnosis of VS are not standardized. The incremental value of three- 
dimensional echocardiography over multiplane transoesophageal two- 
dimensional imaging in the assessment o f VS involving the aortic valve has 
been demonstrated by Samal et al. (58). The following diagnostic criteria can 
be used as suggested by W olf et al. (25) (Table 1.3).
1.15 Diagnosis
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Table 1.3: Diagnostic criteria for the detection of VS by TOE: macroscopic and histopathological characteristics (25).
Criteria Characteristics
1 Based on TOE 1. Hypermobile, filiform, threadlike echodensities, attached to native or prosthetic valves 
(15, 16, 30, 59)
2. Mostly left-sided (15, 31, 33, 59)
3. Lesions not sessile or pedunculate (15)
4. Valve morphology usually normal or minimally thickened (15)
5. Variable length (0.5-4.6 cm), but mostly < 1 cm (15, 59)
2 Macroscopic
examination
1. Slender, filamentous masses (17, 60)
2. Polypoid aspect (17)
3 Histopathology-
Three tissue layers 
(17, 59-61)
1. Central avascular core, densely hyalinised
2. Peripheral layer of loose connective tissue
3. Outer rim of endothelial cells, which may appear hyperplastic
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1.16 Treatment
Definitive therapy for patients with VS and particularly for those who have 
already had an embolic event without another source of embolism is 
undetermined. Freedberg et al. (15) in their study did not find any difference 
in the presence of VS (who also had no other identifiable source o f emboli) 
with respect to use o f anticoagulant or antiplatelet therapy. Cohen et al. (20) 
followed up older ischaemic stroke patients with strands and found the 
incidence rate of stroke was 7.1 per 100- person years in patients receiving 
antiplatelet drugs, 6.9 in those receiving oral anticoagulants, and nil in those 
with no antithrombotic treatment. Roldan et al. (29) found that aspirin or 
warfarin therapy did not appear to have an effect on the prevalence and 
evolution of VS. PICSS, the only randomized treatment study of stroke 
patients with VS showed that neither aspirin nor warfarin had an advantage 
with respect to treatment cfficacy (31). Given that all patients were treated in 
the PICSS study, it remains undefined whether medical therapy altered the 
event rates when compared with untreated patients. There are some ease 
reports describing the use of warfarin in patients with thrombus detected on 
VS (19). Orsinelli and Pearson (33) reported on a patient whom despite a 
prothrombin time in the therapeutic range had a TIA and TOE showed VS 
on his mitral prosthesis. These strands were no longer seen after the addition 
of dipyridamole to his regimen. Loire (62) has suggested surgical resection 
for papillary fibroelastomas (giant LE) as recurrent cerebral embolism has 
been reported despite anticoagulation.
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The optimal treatment remains unclear, but the following guidelines can be 
used.
(a) In patients who undergo TOE for reasons other than suspected 
cardioembolism, the incidental finding o f a valve excrescence probably 
does not warrant the prophylactic use of antiplatelet therapy (29).
(b) If patients have had an embolic event (stroke) and VS is the only 
identifiable cause of stroke, treatment with antiplatelet agents is 
appropriate along with treatment of any other cardiovascular risk 
factors if  present.
(c) In patients after recurrent stroke with VS as the only identifiable cause 
o f stroke, oral anticoagulation or antiplatelet therapy can be considered. 
Surgical resection can also be considered in individual cases.
Treatment of other cardiovascular risk factors remains important.
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2.3 Secondary Aims
(a) To compare the frequency of TOE-defined valvular strands in young and old 
age groups in the stroke cohort patients versus controls.
(b) To determine the relationship o f valvular strands to other potential cardiac 
sources of embolism and diastolic dysfunction on TOE in the stroke cohort 
patients versus controls.
(c) To determine the relationship of TOE-defined valvular strands to ischaemic 
stroke subtype and infarct topography by imaging in the stroke cohort 
patients.
(d) To determine the relationship of hypercoagulable states in young patients 
with or without TOE-defined valvular strands in the stroke cohort patients.
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Chapter 3: Methods
This is a single centre study and all subjects were identified from patients admitted to 
Beaumont Hospital between July 2008 and April 2010 for investigation and treatment 
of stroke. This research project was reviewed by the Ethics (Medical Research)
tinCommittee in Beaumont Hospital and was approved on 10 of July 2008.
3.1 Case-Control study
This is a single-centre observational research study in which the participants were 
identified from patients admitted to Beaumont Hospital between July 2008 and 
April 2010 for investigation and treatment. The main case-control study consists of 
consecutive patients admitted with an acute ischaemic stroke and a control group of 
patients without stroke, with a second prospective part in which only the cohort of 
stroke patients is followed up to identify occurrence of further vascular-related 
outcomes/complications or death (Figure 3.1 and 3.2).
48
--------------------------------------------------------------------------------------------------►
Study onset Time
Figure 3.1: Design of the research study
VS+ Valvular strands present; VS -  Valvular strands absent; 0+  with poor outcome (récurrent infarct/myocardial infarction/vascular death); O - without poor 
outcome
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Figure 3.2: Flow chart of case-control study
TOE = Trans-oesophageal echocardiogram; VS = valvular strands
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3.1.1 Cases
The surveillance for potential study subjects were carried out using the Accident 
and Emergency Department computer system, CT brain logbook, the stroke 
consult service led by the Stroke neurology team and the Acute Stroke Unit, 
which opened in the hospital in the last quarter o f 2009. In addition, daily liaison 
with the neuroradiology department and neurology bed managers and on-call 
medical team also helped to recruit patients. Patients with clinically suspected 
acute ischaemic stroke if  they fulfilled the inclusion and exclusion criteria were 
approached and given verbal and written information concerning the study.
(a) Inclusion criteria
•  All male and female adults aged 16 years or more newly diagnosed with 
acute ischaemic stroke (within 30 days o f onset o f symptoms) based on 
clinical presentation and brain imaging.
•  Written informed consent- prior to the enrolment, all patients were given 
a detailed information leaflet to read and then asked to sign a consent 
form explaining the reasons for and aims o f the study. In the case of 
grossly cognitively impaired patients or with massive stroke or with 
stroke affecting the dominant hemisphere, information leaflets were 
given to the next-of-kin/relative and consent was sought. They were 
asked to sign assent forms as legal representatives.
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(b) Exclusion criteria
•  Patients with primary intracerebral haemorrhage
•  Patients with subarachanoid haemorrhage
• Children and minors (<16 years)
(c) Assessment of cases
After the consent was obtained, patients were assessed as outlined below:
•  A detailed clinical stroke history
•  General, cardiovascular and neurological examination. Neurological 
examination included assigning the National Institute of Health Stroke 
rating Scale (NIHSS) and functional score (Barthel index). See 
appendices 5 and 6.
•  Screening blood tests for hypercoagulable states if  the patients were less 
than 60 years of age. This included prothrombin time, activated partial 
thromboplastin time, international normalised ratio, lupus anticoagulant, 
anticardiolipin antibodies (IgG and IgM), antithrombin III test, protein C 
and protein S, activated protein C resistance, d-dimer, fibrinogen and 
factor V Leiden. Other blood tests performed for this age group included 
complete blood count, erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), vasculitis screen, serum protein electrophoresis and blood 
homocysteine levels. Patients in all age groups underwent fasting 
glucose and lipids.
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•  All patients will undergo noncontrast head CT on admission and 
subsequently MR I brain as repeat imaging unless there is a 
contraindication or any other difficulties. Stroke work-up in order to 
ascertain the mechanism of stroke included a minimum of vascular 
imaging of neck ± brain and cardiac investigations (ECG, 24 hour Holter 
monitoring/telemetry and transthoracic echocardiogram (TTE) / TOE). 
The investigation and management o f patients as a result of their 
participation in the study was not altered. All index stroke will be 
subtyped by a Consultant neurologist with expertise in stroke and will be 
based on a predefined criteria modelled after the National Institute of 
Neurological Diseases and Stroke (N1NDS) Stroke Data Bank and Trial 
of Organon in Acute Stroke Therapy (TOAST) (63).
(d) Trans-oesophageal echocardiography
Transoesophageal echocardiograms were performed using the iE33 Philips 
echocardiography system and mostly by a single Consultant Cardiologist 
with specific expertise in performing and evaluating TOEs. A small number 
of TOEs were performed by Cardiology trainees under his supervision. The 
procedures were focussed on delineation of cardiac source of emboli 
including characterization of VS. VS was defined as a thin filamentous 
material < 1 mm in thickness and extending from the edges of mitral and 
aortic valve, into the left atrium at systole for mitral valve, and into the left 
ventricle at diastole for the aortic valve (20, 27). All the echocardiograms 
were analysed by the same Consultant Cardiologist. TOE performed was 
based on the following criteria:
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•  As a part o f routine clinical care, those patients were there was a high 
index o f suspicion for cardioembolic source based on their stroke 
syndrome and infarct topography on brain imaging and where TTE has 
been negative or not done.
•  As a part of routine clinical care, where stroke syndrome and infarct 
topography were compatible with a cardioembolic mechanism and TTE 
had been an inadequate study because of poor windows or other 
technical factors.
•  As a part of routine clinical care, where stroke syndrome and infarct 
topography were compatible with cardioembolic mechanism and TTE 
shows a possible source, but further definition was required e.g. possible 
thrombus in the left atrial appendage, possible valvular lesion, and 
positive bubble study.
•  As a part of stroke work-up if no other possible mechanisms were 
identified by routine investigations i.e. in cryptogenic stroke.
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Patients without stroke, i.e., controls, were identified serially from the TOE log­
book which provided the details of all the patients who underwent TOE from 
July 2008 to April 2010 in the Cardiology Department o f Beaumont Hospital as 
part of their assessment for all clinical indications. Patients who underwent TOE 
for suspected infective endocarditis were not a valid control group for 
assessment of valvular lesions due to the nature o f their condition and were 
excluded. We also excluded patients who underwent TOE as a part of their 
stroke work-up or to rule out any cardiac source o f emboli. The controls were 
not approached for any clinical assessment and only the following information 
was collected:
•  Medical record number
•  Date of examination
•  Indication for TOE
•  Age of the controls
•  A full TOE report.
There was no matching possible between cases and controls due to lack of 
clinical details (vascular risk factors) for control population.
3.1.2 Controls
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All cases were followed-up for 6 to 12 months by clinic visits to assess the risk of 
recurrent ischaemic stroke, myocardial infarction and or vascular death (defined as 
poor vascular outcome) (Figure 3.3). In the follow-up clinic visits, information 
about any new neurological symptoms, investigations, hospital admissions and 
treatment in the interim were collected. A neurological examination including 
N1HSS score and functional score (BI) were documented. For patients unable to 
attend the follow-up clinic, patients or their carers were interviewed over the 
telephone and information about any new neurological symptoms, investigations, 
hospital admissions, treatment and Bl score were gathered. Their medical notes 
were also reviewed to confirm and to complete the data collected.
3.2 Follow-up study
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Figure 3.3: Flow chart of follow-up study
TOE = Trans-oesophageal echocardiogram; VS + with valvular strands; VS - without valvular strands; O + with poor outcome; O - without poor outcome
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3.3 Statistical methods
3.3.1 Sample size/power calculation
We calculated the sample size required to show a statistically significant 
difference in frequency of valvular strands between cases and controls. We set a 
at 0.05 and the power (1-J3) at 0.90. We used Lehr’s formula: Power = 21 /  
(Standardized difference)2. The standard difference was calculated using the 
formula P ’ = (Pi + P2)/2. We derived Pi (frequency of strands in patients with 
acute ischaemic stroke) at 0.40 from the PICCS study (31) and P2 (frequency of 
strands in control group) at 0.16 from a study done by Robert et al. We 
determined a minimum sample size of 75 in each group (stroke and control) and 
given that approximately 220 patients with stroke were admitted over the 
previous year, reaching the minimum sample size was considered achievable.
We conducted a separate sample size calculation whenever possible to address 
the power issues related to the planned analysis for the secondary outcomes. For 
the association of valvular strands in ischaemic stroke with patient age as a sub­
study (sub-group analysis) we again used Lehr’s formula and Pi and P2 were 
taken from the literature (Pi at 0.52 and P2 at 0.23). We found that a minimum of 
90 patients would be needed in the two age groups (less than 60 years and more 
than 60 years groups).
However, to address the power needed to assess the association between VS and 
ischaemic stroke subtypes, we did not have sufficient data from the literature 
due to different subtyping classifications used and small numbers in each stroke
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subtype reported in the prior studies that investigated this topic (27). No prior 
studies had investigated the association of infarct topography with VS to allow 
us to use them for sample size and power calculations. One prior study reviewed 
the association between antiphospholipids and valvular strands and did not find 
any significant relationship (29). Therefore, no a priori sample size calculation 
and power estimates were available for these two sub-group analyses (in this 
sense, these sub-studies can be also considered as pilot investigations. 
Approximately 220 patients were reviewed by the previous stroke consult 
service over one year. These numbers included haemorrhagic strokes as well. At 
the same time some patients transferred directly from the peripheral hospitals to 
the neurology teams were not included. Overall, given the above calculations, 
we expected to recruit a minimum of 180 patients with stroke and 180 age- 
matched controls over a period of two years.
3.3.2 Statistical analysis
In the case-control study, we used standard descriptive statistics as the first step 
in the analysis o f the data to summarise categorical (qualitative) and continuous 
(quantitative) data and explore if  the latter were normally distributed. Unpaired 
t tests for quantitative data and Chi-square tests o f association for categorical 
data were used to investigate relationships o f interest at a univariate level. 
Univariate analyses as well as multivariate analyses using parametric or logistic 
regression analysis were used to measure the impact of each independent 
variable on the outcome, and where appropriate, to adjust for potential 
confounders. The /»-value of 0.05 is considered as a level of statistical 
significance, unless stated otherwise.
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In the follow-up study, apart from standard descriptive statistics, we have used 
Kaplan-Meier survival curves for the whole stroke cohort as well as survival 
curves based on presence or absence o f valvular strands. Cox proportional 
hazard models were also created including valvular strands, gender and aortic 
valve abnormalities as potential predictors. The SPSS statistical software 
package (version 18) was used for data elaboration and analysis.
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Chapter 4: Results
4.1Demographics of cases
A total of 693 patients admitted with stroke-like symptoms were assessed 
between July 2008 and April 2010 in Beaumont Hospital. There were 300 
patients with confirmed acute stroke clinically and/or radiologically (Figure 3.2). 
Among those, 170 patients fulfilled the inclusion criteria, consented and were 
recruited. Out of these 170 cases, 81 underwent TOE. Information on VS was 
unavailable on three patients and these three patients were excluded from the 
subsequent analysis of VS, leaving 78 patients with TOE for the case-control 
study.
Total number in stroke cohort (follow-up study,) n = 170 
Number of cases in case-control study, n = 78
4.1.1 Age
The whole stroke cohort had a mean age of 58.1 years (SD = 15.7, range
17.2 - 87.2) and showed a bimodal distribution (Figure 4.1) while the cases 
in the case-control study had a mean age of 53 years (SD = 15.1, range 20.5 - 
78.5). The cases were grouped into aged <60 years (young) and >60 years 
(old) for some of the analysis (Table 4.1).
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A ge in y e a rs
Figure 4.1: Age distribution of cases (the whole stroke cohort of patients)
Table 4.1: Age distribution of cases
Demographics Whole stroke cohort, 
n = 170
Case-control study, 
n = 78
Age (mean) in years 58.1±15.7 53.0±15.1
Young (<60 years) 47.6% (81/170) 56.4 % (44/78)
Old {>60 years) 52.4% (89/170) 43.6 % (34/78)
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4.1.2 Gender
Gender distribution showed more males than females (Table 4.2).
4.1.3 Stroke thrombolysis
A total o f 16 (16/170; 9.4%) patients were thrombolysed in the whole 
stroke cohort and three o f them were included in the case-control study.
4.1.4 Medications prior to stroke
Information was available for 169 cases. There were 38.5% (65/169) and 
24.4% (19/78) on antiplatelet agents prior to stroke onset in whole cohort 
and in cases of case-control study respectively (Table 4.3).
4.1.5 Vascular risk Factors
Vascular risk factors for stroke were identified from the whole stroke 
cohort (Table 4.4). One fourth of cases had a history o f some type of 
heart disease (45/170; 26.5%). The most common cardiac diseases 
reported were myocardial infarction and atrial fibrillation (Table 4.5).
4.1.6 Clinical stroke syndrome
Based on the Oxfordshire Community Stroke Project Subtype 
Classification (64), over half of the cases (53.8 % -55.3%) presented 
with partial anterior circulation infarcts with posterior circulation infarcts 
(26.9% - 27.1%) the next most frequent clinical stroke syndrome (Table 
4.6).
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Table 4.2: Gender distribution of cases
Demographics Whole stroke cohort, 
n = 170
Case-control study, 
n = 78
Males (%) 61.2% (104/170) 57.7 % (45/78)
Females (%) 38.8 % (66/170) 42.3 % (33/78)
Table 4.3: Medications prior to stroke
Medication Whole stroke cohort, 
n = 169
Case-control study, 
n = 78
Aspirin 62 (36.7%) 19 (24.4%)
Clopidogrel 13 (7.7%) 3 (3.8%)
Dipyridamole 0 (0%) 0 (0%)
Warfarin 6 (3.6%) 65 (4%)
Dabigatran 0 (0%) 0 (0%)
Antihypertensives 75 (44.4%) 26 (33.3%)
Cholesterol lowering agents 54 (32%) 18 (23.1%)
Diabetic medications 9 (5.3%) 2(3.8%)
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Table 4.4: Vascular risk factors of cases
Risk factors Whole stroke 
cohort, n = 170
Case-control study, 
n = 78
Hypertension 85 (50%) 31 (39.7%)
Diabetes mellitus Type 1 2(1.2%) 0 (0%)
Diabetes mellitus Type 2 13 (7.6%) 5 (6.4%)
Any heart disease 45 (26.5%) 16 (20.5%)
Current smokers 58 (34.1%) 39.7%(31/78)
Ex-smokers 31.8% (54/170) 24.4% (19/78)
Alcohol intake > maximum 
recommended limits
36(21.2%) 13 (16.7%)
Hypercholesterolemia 75 (44.1%) 31 (39.7%)
Peripheral vascular disease 11 (6.5%) 6 (7.7%)
Prior stroke or transient 
ischaemic attack
26(15.3%) 12(15.4%)
History of malignancy 17 (10%) 5 (6.4%)
Migraine 25 (14.7%) 13 (16.7%)
Family history of stroke 56 (32.9%) 25 32.1%)
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Table 4.5: Cardiac diseases in cases
Types of cardiac disease
Frequency
whole stroke 
cohort, n = 170
case-control 
study, n = 78
Atrial fibrillation 17 (10%) 4(5.1%)
Other arrhythmias 4 (2.4%) 3 (3.8%)
Congestive cardiac failure 4 (2.4%) 2 (2.6%)
Angina 13 (7.6%) 4(5.1%)
Myocardial infarction 18 (10.6%) 9(11.5%)
Cardiomyopathy 3 (1.8%) 2 (2.6%)
Left ventricular aneurysm 3 (1.8%) 3 (3.8%)
Valvular heart disease 6(3.5%) 2 (2.6%)
Others ( included patent foramen ovale, 
previous cardiac arrest and infective 
endocarditis)
3 (1.8%) 2 (2.6%)
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Table 4.6: Clinical stroke syndrome of cases: TACI total anterior circulation infarcts, 
PACI partial anterior circulation infarcts, POCI posterior circulation infarcts, LACI 
lacunar infarcts
Stroke subtype Whole stroke cohort, 
n = 170
Case-control study, 
n = 78
TACI 3(1.8% ) 1(1.3%)
PACI 94 (55.3%) 42 (53.8%)
POCI 46 (27.1%) 21 (26.9%)
LACI 16(9 .4% ) 10(12.8%)
TACI and POCI 01 (6%) 1 (1.3%)
PACI and POCI 10(5.9%) 2 (3.8% )
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4.1.7 Stroke severity
At the time of recruitment, stroke severity was measured using National 
Institute o f Health Stroke Scale (NIHSS) and Barthel index (65) for 
activities o f daily living. The median time of assessment for recruitment 
after the stroke onset was 7 days (mean is 7.71 days) and ranged between 
1-29 days. The median NIHSS(66) at the time of recruitment was 3 
(range 0-21) and the median Barthel Index was 100 at the time of 
recruitment (range 0-100). (Table 4.7 and 4.8)
4.1.8 Aetiological classification of ischaemic stroke
Aetiological classification of acute ischaemic stroke was based on The 
Trial of ORG 10172 in Acute Stroke Treatment (TOAST) (63). 
Cardioembolism was the most common mechanism of stroke. Stroke of 
undetermined aetiology constituted 24.1% (41/170) in the whole stroke 
cohort while 30.8% (24/78) were undetermined in cases of case-control 
study (Table 4.9).
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Table 4.9: Stroke subtype based on TOAST criteria (in the order of frequency in the 
whole stroke cohort)
Stroke subtype Whole stroke 
cohort, n = 170
Cases in case-control 
study, n = 78
Cardioembolism 58 (34.1%) 29 (37.2%)
Stroke of other determined 
aetiology
31 (18.2%) 9(11.5%)
Large-artery atherosclerosis- 
embolus/Thrombosis
24 (14.1%) 6 (7.7%)
Small-vessel occlusion (lacune) 16(9.4%) 10 (12.8%)
Stroke of undetermined 
aetiology- incomplete evaluation
16(9.4%) 7 (9.0%)
Stroke of undetermined 
aetiology- negative evaluation
15 (8.8%) 15 (19.2%)
Stroke of undetermined 
aetiology- two or more causes 
identified
10 (5.9%) 2 (2.6%)
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A total o f 89 controls were identified from the logbook of all patients who 
underwent TOE in Beaumont Hospital during the study period. Those who 
underwent TOE for identifying a cardiac source o f emboli (including stroke) or 
to rule out infective endocarditis were excluded. The control group was not 
followed up in the study.
4.2.1 Age
Mean age 63 years (SD =15.4, range 17.7 - 87.9). Controls were 
grouped into young (33.7%; 30/89) and old (66.3%; 59/89) for some 
analyses.
4.2.2 Gender
Males represented 56.2% (50/89) and females were 43.8% (39/89) of all 
patients.
4.2.3 Indications for TOE in controls
The most common indication was atrial fibrillation prior to cardioversion 
followed by assessment for valvular disease (Table 4.10).
4.2Demographics of controls
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Table 4.10: Indications for TOE in controls
Indications of TOE in controls Frequency, 
n = 89
Atrial fibrillation/atrial flutter 39 (43.8%)
Assessment of valvular disease 25 (28.1%)
Others (murmurs, cardiomyopathy, amyloidosis etc.) 16(18%)
Assessment of intra-atrial septum (before/ after closure of 
PFO/ASD)
5 (5.6%)
Assessment of ventricles 4 (4.5%)
72
4.3 Results: Case-control study
Independent-samples t-test was conducted to compare the mean age of cases 
and controls. There was a statistically significant difference in the mean age for 
cases (mean = 53, SD = 15.1) and controls (mean = 63, SD = 15.4) by both the 
Mann-Whitney U test (as a significant difference in the median age) as well as 
the mean age by the t-test (t= -4.26, ¿><0.01, two tailed). The magnitude of the 
difference in the means was -10.08 (95 % Cl: 14.76 to -5.41). The finding that 
the cases were obviously younger than the controls was also seen in the 
statistically significant difference between the proportions of the age groups 
(young and old) among the cases and controls (%2 = 7.79, p=0.005) (Table 
4.11).
On comparing the gender in cases (males = 45 and females = 33) and controls 
(males = 50 and females = 39) by the Chi- Square test, there was no 
statistically significant difference, %2 (1, n = 167) = 0.002, p  = 0.1, phi = -0.02, 
(Table 4.12).
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Table 4.11: Age in cases and controls
Age Cases, n = 78 Controls, n = 89 P value
Age (mean) in years 53.0 63.0 <0.01
Young (<60 years) % 44 (56.4%) 30 (33.7%)
0.005
Old (>60 years) % 34 (43.6%) 59 (66.3%)
Table 4.12: Gender in cases and controls
Gender Cases, n = 78 Controls, n = 89 P value
Males (%) 45 (57.7%) 50 (56.2%)
0.1
Females (%) 33 (42.3%) 39 43.8%)
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VS were identified in 48.7% (38/78) o f cases. The frequency o f VS was 
38.6% (17/44) in young and 61.8% (21/34) in old. Although the 
proportion of VS in the old groups was almost twice as high as that in the 
young group, the Chi-square test did not reveal a statistically significant 
association between age and VS (%2= 3.23,p  = 0.07, phi =0.23) (Table 
4.13).
If the cut-off for creation o f the two age groups in the cases was taken at 
50 years, there was a statistically significant association between age and 
VS (x2 = 6.54, p  = 0.01, phi =0.32).
There was a statistically significant difference in the presence of aortic 
VS, x2 (1, n = 78) = 5.21, p  = 0.02, phi = 0.29 on Chi-Square test (with 
Yates continuity correction) in the two age groups. For mitral VS, the 
Chi- Square test revealed no association between the two age groups, % 
(1, n = 78) =0.77, p  = 0.38, phi = 0.13 (Table 4.14).
Socio-demographic variables, risk factors and stroke characteristics of 
cases with or without valvular strands are described in Table 4.15.
4.3.1 Valvular strands in cases
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Table 4.13: Frequency of VS in the different age groups in the cases
Frequency of VS Young, n = 44 Old, n = 34 P value
Gases 17 (38.6%) 21 (61.8%) 0.07
Table 4.14: Frequency of VS in cases based on location in two age groups
Location of VS Young, n = 44 Old, n = 34 P value
Mitral VS 14(31.8%) 15(44.1%) 0.38
Aortic VS 4(9.1% ) 11 (32.4%) 0.02
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Table 4.15: Socio-demographic variables, risk factors and stroke characteristics of 
cases with or without valvular strands
Variable With VS, n = 38 Without VS, n = 40 P  value
Age 58.0±13.9 48.2±14.9 0.004
Male 20 (52.6%) 25 (62.5%) 0.514
Hypertension 18(47.4%) 13 (32.5%) 0.267
Diabetes 4 (10.5%) 1 (2.5%) *0.195
Any heart disease 11 (28.9%) 5 (12.5%) 0.129
Valvular heart 
disease
1 (2.6%) 1 (2.6 %) *1.000
Current Smoking 17(44.7%) 14 (35%) 0.158
Alcohol intake** 5 (13.2%) 8 (20%) 0.612
Hypercholesterolemia 18 (47.4%) 13(32.5%) 0.269
Prior antiplatelet 
agents
11 (28.9%) 8 (20%) 0.512
NIHSS (mean ±SD) 3.53 ±3.25 3.13± 3.6 0.612
BI (mean ±SD) 85.92 ±27.82 91.03± 22.7 0.380
*Fisher ‘s exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable. ** Alcohol intake > maximum recommended limits
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VS were identified in 32.6% (29/89) of controls. The frequency o f VS in 
young was 30% (9/30) and in the old was 33.9% (20/59) (Table 4.16). 
There was no significant association between young and old in the 
presence of VS overall [x2 (1, n  = 89) = 0.02,p  = 0.90, phi =0.04] or on 
individual valves (mitral or aortic) in the Chi-Square test (Table 4.17).
There was no statistically significant association between the young and 
old age groups o f controls in the presence of VS, % (1, n=89) = 0.001,p  
= 0.98, phi =0.03 even if  the cut off for age groups was lowered to 50 
years.
4.3.2 Valvular strands in controls
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Table 4.16: Frequency of VS in controls based on age groups
Frequency of VS Young, n = 30 Old, n = 59 P  value
Controls 30.0% (9/30) 33.9% (20/59) 0.89
Table 4.17: Frequency of VS in controls based on location in two age groups
Location of VS Young, n = 30 Old, n = 59 P  value
Mitral VS 7 (23.3%) 6 (10.2%) 0.18
Aortic VS 3 (10.0%) 14(23.7%) 0.20
Table 4.18: Frequency of VS in controls based on referral diagnosis
Indications of TOE in controls Frequency, 
n = 89
Frequency of VS, 
n = 29
Atrial fibrillation/atrial flutter 39 (43.8%) 13 (44.8%)
Assessment of valvular disease 25 (28.1%) 5 (17.2%)
Others (murmurs, cardiomyopathy, 
amyloidosis etc.)
16(18%) 7(24.1%)
Assessment of intra-atrial septum 
(before/ after closure of PFO/ASD)
5 (5.6%) 3 (10.3%)
Assessment of ventricles 4 (4.5%) 1 (3.4%)
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VS as defined by TOE were identified in 48.7% (38/78) o f cases and 
32.6% (29/89) o f controls. There was an association although marginal, 
between TOE-defined VS and the occurrence o f acute ischaemic stroke 
we found that the risk for stroke in the patients with VS was more than 
three times the risk of patients without VS (OR = 3.85, %2 (1, n = 167) = 
3.85,p  = 0.05, phi = -0.16, Table 4.19).
Chi-square testing revealed a statistically significant association in older 
cases and controls in the presence of VS [x2 (1, n = 93) = 5.71, p  = 0.017, 
phi =0.27] (Table 4.20).
4.3.3 Valvular strands between cases and controls
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Table 4.19: Frequency of VS between cases and controls
Case-control study Cases, n = 78 Controls, n = 89 P value
Frequency of VS 38 (48.7%) 29 (32.6%) 0.05
Table 4.20: Frequency of VS in two age groups of case-control study
Frequency of VS in Cases Controls P  value
Young 38.6% (17/44) 30% (9/30) 0.60
Old 61.8% (21/34) 33.9% (20/59) 0.01
Total 48.7% (38/78) 32.6% (29/89) 0.05
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Among 38 cases with VS, the VS were located on the mitral valve in 23 
(60.5%), the aortic valve in 9 (23.7%) and both mitral and aortic valves 
in 6 (15.8%). Among 29 controls with VS, 11 (39.3%) had VS only on 
mitral valve, 15 (53.6%) had VS on aortic valve, two (7.1%) had VS on 
both mitral and aortic location and one had VS on tricuspid valve (Table
4.21). There were no VS noted on the tricuspid valve in cases. Neither 
cases nor controls had VS on the pulmonary valve.
In other words, among the cases, o f the total 44 valves with strands, 29 
were on mitral and 15 on aortic valves. In controls, of the total 31 valves 
with strands, 13 were on mitral and 17 were on aortic valves (Table
4.22). Chi-square testing revealed a statistically significant association 
between cases and controls in the presence o f mitral VS [x (1, n = 167) = 
10.08,/? = 0.001, phi =0.26].
Among the total 78 mitral valves in the cases, 48 (61.5%) were 
thickened. Of the 48 thickened mitral valves, 43.8% (21/48) had VS. 
Among the 30 mitral valves without any thickening, 26.7% (8/30) had 
VS (Table 4.23). In other words, 72.4% (21/29) of mitral valves with VS 
had valve thickening compared to 55.1% (27/49) of mitral valves without 
VS, x2 (1, n = 78) = 1.63,/? = 0.20, phi =0.17.
4.3.4 Frequency of VS based on location
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Table 4.21: Frequency of left-sided VS in cases and controls
Location Cases with VS, n = 38 Controls with VS, n = 28*
Mitral VS 60.5% (23/38) 39.3% (11/28)
Aortic VS 23.7% (9/38) 53.6% (15/28)
Both mitral and 
aortic VS
15.8% (6/38) 7.1% (2/28)
*n = 28 as one patient with VS on tricuspid valve excluded from analysis.
Table 4.22: Frequency of VS in cases and controls
Location of VS Cases, n = 78 Controls, n = 89 P  value
Mitral VS 37.2% (29/78) 14.6% (13/89) 0.001
Aortic VS 19.2% (15/78) 19.1% (17/89) 1.000
Table 4.23: Mitral valve thickening and VS
Mitral valve Thickened, n = 48 Not thickened, n = 30
VS+ (n = 29) 21 8
VS- (n = 49) 27 22
KS’ i valvular strands present, VS- valvular strands absent
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When all mitral valvular abnormalities were combined, there was no 
statistically significant association between presence of mitral VS and 
mitral valve abnormalities, x,2 ( 1, n = 78) = 1.49, p  = 0.22, phi =0.17. 
Mitral valvular abnormalities included were valve thickening, 
calcification, myxomatous changes and stenotic or regurgitant 
valvular abnormalities with greater than mild in severity.
Similarly, there was no statistically significant association between 
aortic valve abnormalities and presence o f aortic VS, x2 (1, n = 78) = 
0.00,/? = ! .00, phi = 0.00. Aortic valvular abnormalities included 
were aortic sclerosis and stenotic or regurgitant valvular 
abnormalities greater than mild in severity.
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Possible cardiac sources o f emboli were categorised into medium and 
high-risk factors according to TOAST criteria.
(a) Cases : Among the medium-risk cardiac sources o f emboli, 
hypokinesis o f left ventricle (LV) was found in 13 % (5/38) of 
cases with VS and was associated with VS ip = 0.02). No other 
medium-risk or high-risk cardiac sources o f emboli had a 
statistically significant association with VS on further analysis, 
(Table 4.24 and Table 4.25). When all possible cardiac sources 
o f emboli (including other recognised cardiac sources o f emboli 
such as aortic plaques) were combined, Chi-square testing did not 
reveal any statistically significant association between presence 
or absence of VS and other possible cardiac sources o f emboli in 
cases lx2 (2, n = 78) = 3.78, p  = 0.15, phi =0.22], (Table 4.26).
4.3.5 Valvular strands and other cardiac sources of emboli in TOE
85
Table 4.24: Valvular strands and other medium-risk (63) cardiac sources of emboli
in cases
Medium-risk 
source of emboli
With VS, n = 38 Without VS, n = 40 P  value
PFO with R- L shunt 9 (23.7%) 8 (20%) 0.91
ASD with R -  L shunt 1 (2.6%) 1 (2.5%) *1.00
Atrial septal aneurysm 12(31.6%) 11 (27.5%) 0.88
SEC in LA/LAA 3 (7.9%) 2 (5%) *0.67
Mitral annular 
calcification
1 (2.6%) 1 (2.5%)
*1.00
Hypokinesis of LV 5 (13.2%) 0 (0%) *0.02
Mitral valve prolapse 3 (7.9%) 0 (0%) *0.11
Atrial flutter 0 (0%) 0 (0%) -
MS without atrial 
fibrillation
1 (2.6%) 0 (0%) *0.49
All medium risk 
factors based on 
TOAST criteria
21 (58.3%) 15 (41.7%) 0.18
*Fisher's exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable.
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Table 4.25: Valvular strands and other high-risk (63) cardiac sources of emboli in
cases
High-risk source of 
emboli
With VS, n = 38 Without VS, n = 40 P  value
Atrial fibrillation 1 (2.6%) 2 (5%) *1.00
Thrombus in LA, LAA 
or LV
0 (0%) 0 (0%)
Akinesis or global 
hypokinesis of LV
0 (0%) 0 (0%)
Cardiomyopathy 0 (0%) 0 (0%) *
Infective endocarditis 0 (0%) 1 (2.5%) *1.00
Mass lesion 2 (5.3%) 0 (0%) *0.23
All high risk factors 
based on TOAST criteria
1 (2.6%) 3 (7.5%) *0.62
Aortic plaques grade 2, 3 
and 4
18(47.4%) 11 (27.5%) 0.11
Aortic plaques 3 and 4 5(13.1%) 1 (2.5%) *0.10
*Fisher’s exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable.
Table 4.26: Possible cardiac source of emboli in cases with valvular strands
Possible cardiac source of in cases with VS Frequency, n = 38
No risk factors 14 (36.8%)
Medium risk factor/s 16(42.1%)
High risk factor / both medium and high risk factors 8 (21.1%)
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In controls, there was a statistically significant association 
between atrial flutter (p =  0.03) in medium-risk and thrombus in 
left atrium/ left atrial appendage (p = 0.04) in high-risk cardiac 
sources of emboli and VS, (Table 4.27 and Table 4.28).
When all possible cardiac sources o f embolism (including other 
recognised cardiac sources o f emboli such as aortic plaques) were 
combined, Chi-square testing did not reveal any statistically 
significant association between presence or absence of VS and 
cardiac sources of emboli in controls, x (2, n = 89) = 0.70, p  = 
0.70, phi =0.09.
(b) Controls:
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Table 4.27: Valvular strands and other medium-risk cardiac sources of emboli in
controls
Medium-risk source 
of emboli
With VS, n = 29 Without VS, n = 60 P  value
PFO with R- L shunt 1 (3.4%) 4 (6.7%) *1.00
ASD with R -  L shunt 0 (0%) 1 (1.7%) *1.00
Atrial septal aneurysm 1 (3.4%) 5 (8.3%) *0.66
SEC in LA/LAA 12(41.4%) 20 (33.3%) 0.61
Mitral annular 
calcification
1 (3.4%) 4 (6.7%)
*1.00
Hypokinesis of LV 4(13.8%) 8 (13.3%) *1.00
Mitral valve prolapsed 4(13.8%) 4 (6.7%) *0.43
Atrial flutter 3 (10.3%) 0 (0%) *0.03
MS without atrial 
fibrillation
0 (0%) 0 (0%)
All medium risk factors 
based on TOAST criteria
22 (75.9%) 35 (58.3%) 0.17
*Fisher's exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable.
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Table 4.28: Valvular strands and other high-risk cardiac sources of emboli in 
controls
High risk source of 
emboli
With VS, n = 29 Without VS, n = 60 P value
Atrial fibrillation 12(41.4%) 27 (45%) 0.93
Thrombus 4(13.8%) 1 (1.7%) *0.04
Akinesis or global 
hypokinesis of LV
5(17.2%) 5 (8.3%) *0.28
Cardiomyopathy 1 (3.4%) 2 (3.3%) *1.00
Infective endocarditis 
(Not included in the 
study)
Mass iesion 1 (3.4%) 1 (1.7%) *0.55
Aortic plaques grade 
2, 3 and 4
16 (55.2%) 28 (46.7%) 0.60
Aortic plaques 3 and 4 5 (17.2%) 13 (21.7%) 0.84
High risk factors based 
on TOAST
18(62.1%) 30 (50%) 0.40
* Fisher’s exact probability test is used when the rule for the minimum necessaiy cell count for the Chi- 
Square test is violated and the latter is not applicable.
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Diastolic dysfunction refers to abnormal mechanical properties of the 
myocardium. This includes abnormal left ventricular diastolic 
distensibility, impaired filling, and slow or delayed relaxation- regardless 
of whether the ejection fraction is normal or depressed and whether the 
patient is asymptomatic or symptomatic (67).
In cases with VS, 30/38 (78.9%) had diastolic dysfunction while in cases 
without VS only 21/40 (52.5%) had diastolic dysfunction. There was a 
statistically significant association [x2 (1, n = 78) =4.91, p  = 0.03, phi = 
0.28] between the presence of VS and diastolic dysfunction in cases.
In controls with VS, 11/29 (37.9%) had diastolic dysfunction while 
17/60 (28.3%) without VS had diastolic dysfunction and Chi-square test 
did not reveal any statistically significant association, x (1, n = 89) = 
0.45, p  = 0.50, phi = 0.09.
Case-control study: The Chi-square test revealed a statistically 
significant association between diastolic dysfunction in cases and 
controls with VS, % (1, n = 167) = 7.75, p  = 0.005, phi = 0.23.
4.3.6 Valvular strands and diastolic dysfunction
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I4.3.7 Valvular strands and hypercoagulable states
In the whole stroke cohort of cases, there were 81 (81/170; 47.6%) 
young (<60 years) patients. Laboratory blood tests were performed in 74 
(74/81; 91.4%>) of these patients to rule out hypercoagulable states. 
Among these 74 patients, 27 were found to have completely normal tests 
and 47 patients (47/74; 63.5%>) with some abnormalities. There were 
only 16 patients found to have abnormalities such as low protein C, low 
protein S, low antithrombin III, APC resistance with Factor V Leiden, 
lupus anticoagulant and elevated anticardiolipin antibodies, (Figure 4.2).
In the case-control study, out of 43 (43/78; 55.1%) cases had been tested 
for hypercoagulable conditions by laboratory testing, only 9 (9/43; 
20.9%) patients were found to have abnormalities as explained above 
and two of them had VS in TOE, (Table 4.29).
In 81 young cases, 56 patients were tested for homocysteine levels in 
blood and three of them had mildly elevated levels.
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Figure 4.2: Valvular strands and hypercoagulable states in laboratory testing
Table 4.29: Valvular strands and hypercoagulable states on laboratory testing in 
young cases.
Hypercoagulable
state
With VS, n = 17 Without VS, n = 26 P  value
Present 2(11.8%) 7 (26.9%)
*0.281
Absent 15 (88.2%) 19(73.1%)
*Fisher's exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable.
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The most common stroke subtype was cardioembolic irrespective of the 
presence or absence of VS. The distribution of VS in the 38 cases was as 
follows: 16 (42.1%) with cardioembolic stroke, 7 (18.4%) with 
cryptogenic stroke with negative evaluation, 5 (13.2%) in small vessel 
disease, 4 (10.5%) in cryptogenic stroke with incomplete evaluation, 3 
(7.9%>) in stroke of other determined aetiology, 2 (5.3%) in large-artery 
atherosclerosis and 1 (2.6%) in stroke with two or more causes 
identified, (Table 4.30).
Cardioembolism and valvular strands: Sixteen of 38 patients with VS 
and 13 out of 40 patients without VS were found to have a cardiac source 
of embolism as stroke aetiology, (Table 4.31). The Chi- Square test did 
not reveal any significant association between cases with or without VS 
and presence of a cardiac source of embolism, %2 (1, n = 78) =0.41 , p  = 
0.52, phi = 0.1.
Cryptogenic stroke and valvular strands: Twelve of 38 patients with VS 
and 12 out of 40 patients without VS were found to have cryptogenic
strokes, (Table 4.32). The Chi-square test did not reveal any significant
♦ 2 association between cases with or without VS and cryptogenic stroke, %
(1, n = 78) =0.00,/? = 1, phi = -0.02.
4.3.8 Valvular strands and Stroke subtypes
94
Table 4.30: Valvular strands and Stroke subtypes
Stroke subtype With VS, n = 38 Without VS, n = 40
Large-artery atherosclerosis 2 (5.3%) 4(10%)
Cardioembolism 16(42.1%) 13 (32.5%)
Small-vessel occlusion 5(13.2%) 5 (12.5%)
Stroke of other determined 
aetiology
3 (7.9%) 15% (6/40)
Undetermined aetiology- 
two or more causes
1 (2.6%) 1 (2.5%)
Undetermined aetiology- 
negative evaluation
7(18.4%) 8 (20%)
Undetermined aetiology- 
incomplete evaluation
4(10.5%) 3 (7.5%)
95
Table 4.31: Cardioembolic stroke and valvular strands
Stroke subtype With VS, n = 38 Without VS, n = 40 P value
Cardioembolism 16(42.1%) 13(32.5%) 0.52
Table 4.32: Cryptogenic stroke and valvular strands
Stroke subtype With VS, n = 38 Without VS, n = 40 P value
Cryptogenic (all 
three undetermined 
groups combined)
12(31.6%) 12(30%) 1.00
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On admission, among the total 170 cases, 85.3% (145/170) underwent 
noncontrast head CT and 14.7% (25/170) MRI brain as their initial brain 
imaging. Repeat brain imaging was performed in 84% (143/170) and the 
majority underwent MRI brain imaging (98.6%). MRI brain imaging was 
available for 160 (94.1%) cases to study the infarct topography. The 
infarcts were most common in subcortical location in cases either with or 
without VS in TOE. In 54 (54/78; 69.2%>) cases with subcortical infarcts 
approximately half of them had VS. Similarly the proportion of cases 
with VS was almost equal in cases with cortical and cerebellar infarcts. 
The Chi-square test showed no significant association between presence 
of VS and location of infarct (infarct topography), Table 4.33. Similarly, 
in cryptogenic stroke, infarcts were more frequently found in subcortical 
location and there is no difference in the presence of VS in infarcts on 
four locations studied.
The infarcts were commonly found on the left side on neuroimaging 
irrespective of the presence or absence of VS (Table 4.34). There was no 
statistically significant association between the side of infarct location 
and presence of VS, x2 (2, n = 78) =4.97, p  = 0.08, phi = -0.25. Among 
cases with VS, there were 8 with mild, 22 with moderate and 7 with 
severe white matter changes on comparison to 14, 19 and 6 patients 
respectively in patients without VS. There was no statistically significant 
association found on Chi-square test, % (2, n = 76) =1.88, p  = 0.39, phi = 
0.16.
4.3.9 Valvular strands and in farct topography
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Table 4.33: Valvular strands and infarct topography
Infarct location With VS, n = 38 Without VS, n = 40 P  value
Cortical 18 (47.4%) 20 (50%) 1.00
Subcortical 26 (68.4%) 28 (70%) 1.00
Brainstem 4(10.5%) 6 (15%) *0.74
Cerebellar 6(15.8%) 6 (15%) 1.00
*Fisher's exact probability test is used when the rule for the minimum necessary cell count for the Chi- 
Square test is violated and the latter is not applicable.
Table 4.34: Valvular strands and location (side) of infarcts
Infarct location With VS, n = 38 Without VS, n = 40 P  value
Left side 16 (42.1%) 26 (65%)
0.08Right side 14 (36.8%) 11 (27.5%)
Both sides 8 (21.1%) 2 (7.5%)
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In the case-control study, univariate regression analyses of different 
variables including valvular strands, age, gender, atrial fibrillation, 
diastolic dysfunction, aortic and mitral valvular abnormalities were 
performed. The p  value for all the variables except gender was 
statistically significant {p <0.05), (Table 4.35).
Valvular strands on mitral valve location were associated with stroke at 
univariate analysis with an Odds ratio of 0.29, (95 % Cl 0.14-0.61),/? = 
0.001, (Table 4.36).
Univariate logistic regression analysis showed no statistically significant 
association between aortic valve abnormalities and presence of aortic VS 
{p = 0.982). Aortic valve abnormalities included aortic sclerosis and 
valvular disease (trivial or mild aortic stenosis or regurgitation were not 
included). Similarly there was no statistically significant association 
between mitral valve abnormalities and presence of mitral VS (p = 
0.144). Mitral valve abnormalities included valve thickening, 
calcification, myxomatous changes and valvular disease (trivial or mild 
mitral regurgitation or mitral stenosis were not included).
4.3.10 Case-control study: Univariate regression analysis
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Table 4.35: Univariate regression analysis of different variables in case-control study
Variable B S.E Wald df Sig Odds ratio 95 % C.I for Odds ratio
Lower Upper
Valvular strands 0.68 0.32 4.46 1 0.035 1.97 1.05 3.68
Age -0.04. 0.01 15.16 1 0.000 0.96 0.94 0.98
Young and old 0.93 0.32 8.52 1 0.004 2.55 1.36 4.77
Gender 0.06 0.31 0.04 1 0.844 1.06 0.58 1.97
Atrial fibrillation 2.97 0.63 22.49 1 0.000 19.50 5.713 66.56
Diastolic dysfunction 1.42 0.33 18.40 1 0.000 4.12 2.16 7.85
Aortic valve abnormalities 1.59 0.34 21.85 1 0.000 4.90 2.519 9.57
Mitral valve abnormalities 1.07 0.42 6.42 1 0.011 2.91 1.27 6.65
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f degrees of 
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
100
Table 4.36: Univariate regression analysis of types of VS and stroke
Variable B S.E Wald df Sig Odds ratio 95% C.I for Odds ratio
Lower Upper
Mitral VS -1.241 0.38 10.63 1 0.001 0.29 0.14 0.61
Aortic VS -0.01 0.39 0.00 1 0.983 0.99 0.46 2.15
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant. Wald Wald Chi-square test, d f  degrees of 
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
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A two-level logistic regression approach was used to fit a multivariate 
regression model and test for relationship between the presence o f VS 
and acute ischaemic stroke. There were no corrections made for multiple 
comparisons in our study. As a first step, 6 variables that are significant 
at P < 0.05 from the univariate analysis were included as potentially 
independent predictors- valvular strands, age, mitral valve abnormalities, 
aortic valve abnormalities, atrial fibrillation and diastolic dysfunction in 
TOE- in the initial regression model. As shown in Table 4.37, only one 
variable (mitral valve abnormality which had a significance level p  
>0.05) was removed at step 1. In the second step, the Odds ratio of 
predicting stroke by the presence of valvular strands is 2.15 (95% Cl 
0.95- 4.85) and had a p  value of 0.065, (Table 4.38). Even though the 
significance is marginal, there was over two times chance o f having an 
acute ischaemic stroke with presence of VS. All other variables 
remaining in step 2 o f the model were found to have a p  value < 0.05. 
The strongest predictor o f stroke was atrial fibrillation with an Odds ratio 
of 10.95 (95% Cl 2.81-42.67).
Notably the final model was constructed o f five factors with 84.6%> 
sensitivity and 83.1% specificity and correctly identified 83.8%) of cases 
overall.
4.3.11 Case-control study: Multivariate logistic regression
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Table 4.37: Two-level logistic backward stepwise (conditional) regression analysis of valvular strands in acute ischaemic stroke
(Step 1)
Variables B S.E. Wald df Sig. Exp(B)
95% C.I. for Exp(B)
Lower Upper
Step 1 Valvular strands .828 .419 3.912 1 .048 2.290 1.008 5.204
Age -.025 .013 3.452 1 .063 .975 .950 1.001
Aortic valve abnormality 1.479 .457 10.466 1 .001 4.387 1.791 10.743
Mitral valve abnormality .942 .586 2.587 1 .108 2.565 .814 8.084
Atrial fibrillation 2.341 .706 10.995 1 .001 10.388 2.604 41.440
Diastolic dysfunction 1.170 .458 6.534 1 .011 3.223 1.314 7.906
Constant -2.336 1.128 4.290 1 .038 .097
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f degrees o f 
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation of the B coefficient, which is an Odds ratio
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Table 4.38: Two-level logistic backward stepwise (conditional) regression analysis of valvular strands in acute ischaemic stroke
(Step 2)
Variables B S.E. Wald Df Sig. Exp(B)
95% C.I. for Exp(B)
Lower Upper
Step 2 Valvular strands .765 .415 3.400 1 .065 2.149 .953 4.845
Age -.028 .013 4.261 1 .039 .973 .948 .999
Aortic valve abnormality 1.662 .444 13.983 1 .000 5.270 2.205 12.592
Atrial fibrillation 2.394 .694 11.903 1 .001 10.954 2.812 42.671
Diastolic dysfunction .980 .434 5.100 1 .024 2.665 1.138 6.242
Constant -1.980 1.093 3.279 1 .070 .138
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f degrees of 
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
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Among the total 170 patients, 161 (94.7%) patients completed follow-up on 
time. The majority were seen in outpatient clinics (150/161) and the minority 
who were unable to attend the clinics for various reasons were interviewed by 
telephone (11/161). The median time to follow- up was 251.5 days (SD 171.78, 
range 28-883 days). Two patients refused to attend follow-up clinics and 7 
patients (4.1%>) died.
4.4.1 Vascular risk factor control
Hypertension: Prior to recruitment, there were 50% (85/170) o f cases had 
a history of hypertension. At the time of follow-up, 53.3% (81/152) of 
the cases had their blood pressure well controlled (criteria used was 
<135/85 mm of Hg for non-diabetics and <130/80 mm of Hg for 
diabetics), (Table 4.39).
Smoking: There was a 50%> reduction in smoking at follow-up, (Table 
4.40).
Alcohol intake: The alcohol intake over the maximum recommended 
limit was reduced from 21.2% at recruitment to 6.4%> at follow-up,
(Table 4.40).
Cholesterol levels: Cholesterol levels were high in similar proportion of 
cases at follow-up compared to the levels at recruitment, but, only 69.2% 
of cases underwent testing for the same at follow-up, (Table 4.41).
4.4Results: Follow-up study
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Glucose levels: Two thirds o f cases underwent testing at follow-up, 8.8 
% and 4.4% had serum glucose levels >7mmol/l and impaired fasting 
glucose (6.1 - 6.9 mmol/1) respectively, (Table 4.42).
4.4.2 Medications at follow-up
At follow-up, 86.3% were on antiplatelet agents compared to 38.5% 
prior to the index stroke. There were 68.8%) cases on antihypertensive 
medications and 87.5%> on cholesterol lowering agents at follow-up. The 
use of oral anticoagulants was increased from 3.6%> at the time of 
recruitment to 36% of cases at follow-up, (Table 4.43).
4.4.3 Recovery from stroke
NIH stroke score (NIHSS) was estimated from all 150 patients who 
attended the outpatient clinics for follow-up and the median NIHSS was 
0 (range 0-7). The median Barthel score was 100 (range 25-100) at 
follow-up and was available for all 161 patients had follow-up, (Table 
4.44 and Table 4.45).
4.4.4 Repeat TOEs at follow-up
Eight patients underwent repeat TOE before their follow-up. Of those 8 
patients, one patient had VS on mitral valve in the first TOE and was 
found to have VS not only on the same location but also at a new 
location (aortic valve) in the repeat TOE. The details of all those eight 
patients underwent repeat TOE are described in Table 4.46.
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Table 4.39 Vascular risk factor control- Hypertension
At recruitment: known 
hypertensives, n = 170
Blood pressure at follow-up, n = 152
Controlled Uncontrolled
85 (50%) 81 (53%) 71 (46.7%)
Table 4.40: Vascular risk factor control- Smoking and alcohol intake
Variables At recruitment At follow-up
Current smokers 34.1% (58/170) 17% (27/159)
Alcohol >max recommended limit 21.2% (36/170) 6.4% (10/156)
Table 4.41: Vascular risk factor control- Cholesterol levels
Cholesterol level At recruitment, 
n = 170
At follow-up, 
n = 159
Normal 70 (41.2%) 48 (30.2%)
Low HDL, others normal 20 (11.8%) 7 (4.4%)
High 59 (34.7%) 55 (34.6%)
Tests not done 21 (12.4%) 49 (30.8%)
As per the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and 
treatment o f high cholesterol in adults guidelines (68), for patients with atherosclerotic ischemic stroke 
or TIA and without known CHD, it is reasonable to target a reduction o f at least 50% in LDL-C or a 
target LDL-C level o f <70 mg/dL (to obtain maximum benefit) (Class II a; Level o f Evidence B).
1 mmol = 39 mg/dL; 70 mg/dL is approx 1.8 mmol/L
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Table 4.42: Vascular risk factor control- Glucose levels
Serum glucose level At recruitment, n = 170 At follow-up, n = 160
Normal * 104 (61.2%) 94 (58.8%)
Impaired** 18(16.6%) 7 (4.4%)
High*** 21 (12.4%) 14 (8.8%)
Tests not done**** 27 (15.9%) 45 (28.1%)
*3.6-6.0 mmol/L, **6.1-6.9 mmol/L, ***>7 mmol/L, **** Included some o f the known diabetic patients 
on treatment.
Table 4.43: Medications at follow-up
Medications Prior to stroke, n = 169 At follow-up, n = 161
Aspirin 62 (36.7%) 128 (79.5%)
Clopidogrel 13 (7.7%) 51 (31.7%)
Dipyridamole 0 (0%) 12 (7.5%)
any antiplatelet agents 65 (38.5%) 139 (86.3%)
Oral anticoagulants * 6 (3.6%) 58 (36%)
Antihypertensives 75 (44.4%) 110(68.8%)**
Diabetic medications 9 (5.3%) 15 (9.3%)
Cholesterol lowering 
medications
54 (32%) 140 (87.5%)*
* Warfarin, dabigatran, **n -  160
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Table 4.44: Recovery from stroke- NIHSS at follow-up
NIHSS At recruitment, n = 169 At follow-up, n = 150
Mild (score < 6) 76.3% (129/169) 95.3% (143/150)
Moderate (score 6- 13) 20.1% (34/169) 4% (6/150)
Severe (score > 14) 3.6% (6/169) 0% (0/150)
Table 4.45: Functional score (Barthel Index) at follow-up
Barthel index At recruitment, n = 169 At follow-up, n = 161
Favourable (> 95) 103 (60.9%) 130 (80.7%)
Unfavourable (< 95) 66 (39.1%) 66 (39.1%)
109
Table 4.46: Repeat TOE at follow-up
Patients First TOE Second TOE
VS Other findings VS Other findings
Patient 7 No ASD, quadricusp AV No ASD, quadricusp 
AV
Patient 142 No PFO with R-L shunt, 
ASA
No PFO closure device 
well seated
Patient 146 No - No No CSOE
Patient 150 No Large vegetations at 
AV (IE)
No Prosthetic AV and 
no vegetations
Patient 151 Mitral VS Thickening of right 
coronary cusp of AV
Mitral and 
aortic VS
Patient 160 No PFO with R-L shunt, 
ASA
Aortic VS Well seated PFO 
closure device
Patient 163 No PFO with R-L shunt, 
ASA
No Well seated PFO 
closure device
Patient 168 No Tiny PFO with L-R 
shunt, poor valsalva 
manoeuvre
No PFO with R-L 
shunt, ASA, MVP
First TOE- TOE performed as a part o f stroke work-up, Second TOE- TOE performed after the first TOE
before the follow-up had completed, ASD atrial septal defect, AV aortic valve, AS aortic stenosis, PFO 
patent foramen ovale, R-L right to left, ASA atrial septal aneurysm, CSOE cardiac source o f  emboli, IE 
infective endocarditis, MVP mitral valve prolapse.
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4.4.5 Stroke-like symptoms at follow-up
Since the discharge from the index stroke there were 44 patients [26.3% 
(44/167)] admitted to hospital due to various reasons and are described in 
Table 4.47. There were 28 patients [16.8 % (28/167)] reported to have 
had new stroke-like symptoms since their index stroke but only 7 
patients (7/28; 25%>) had confirmed acute infarct on neuroimaging,
(Table 4.48). In 10 patients although no acute infarct was found, the 
aetiology of their symptoms were unclear.
4.4.6 Outcome of whole stroke cohort
‘Poor vascular outcome’ has been defined as fatal and non fatal vascular 
events. Vascular events included TIA, ischaemic stroke and myocardial 
infarction. ‘Poor combined outcome’ included all deaths and all vascular 
events.
Two patients had recurrent TLA. and 7 had recurrent ischaemic stroke. 
Four patients had confirmed myocardial infarction. There were 7 deaths 
in the whole stroke cohort and five o f them were vascular deaths. Poor 
vascular outcome and poor combined outcome were recorded in 16 and 
17 patients respectively at the time of follow-up. Table 4.49 shows the 
different aspects o f the outcome in the whole stroke cohort.
I l l
Table 4.47: Recurrent hospital admission- Causes
Causes of hospital admission Frequency, n = 44
Stroke related 20 (45.5%)
Cardiac cause 7(15.9%)
Both stroke and cardiac related 1 (2.3%)
Bleeding related to antiplatelet agents/anticoagulants 4(9.1%)
Others 12 (27.3%)
Table 4.48: Stroke-like symptoms at follow-up: Diagnosis
Stroke-like symptoms- Diagnosis Frequency, n = 28
Post stroke epilepsy 8 (28.6%)
TIA 2(7.1%)
Confirmed acute infarct 7 (25%)
CADASIL encephalopathy 1 (3.6%)
Unclear diagnosis but no evidence of acute stroke on 
neuroimaging
10(35.7%)
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Table 4.49: Outcome of whole stroke cohort
Outcome Frequency
Recurrent ischaemic stroke 4.2% (7/167)
Recurrent TIA/ ischaemic stroke 5.4% (9/167)
Myocardial infarction 2.4% (4/167)
Vascular death 2.9% (5/170)
Death from all causes* 4.1% (7/170)
Poor vascular outcome (vascular events** and vascular 
death)
9.5% (16/168)
Poor combined outcome (all deaths and all vascular 
events)
10.1% (17/168)
Two patients refused to attend follow-up clinic or telephonic interview.
*The causes o f death included recurrent ischaemic stroke (2/7), complications from existing malignancy 
(2/7), and from respiratory and cardiac complications post stroke (2/7). One patient had sudden 
unexpected death and consensus was o f a vascular death, the exact cause o f death was unavailable.
** Vascular events include TIA, stroke and myocardial infarction.
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There were 16 events which can be classified as “poor vascular 
outcome” in the whole stroke cohort. Poor vascular outcome included 
fatal and non fatal vascular events. Vascular events included TIA, 
Ischaemic stroke and myocardial infarction.
The survival curve of the whole stroke cohort from poor vascular 
outcome is shown in Figure: 4.3. The mean survival time was 777.30 
days (Std. Error 26.79, 95% Ci: 724.80- 829.80).
Kaplan-Meier survival curves in stroke cohort with or without valvular 
strands from poor vascular outcome were not statistically significant 
different from one another, (Figure 4.4).
Univariate logistic regression analysis of the variables including valvular 
strands, age, gender, some TOE findings, antiplatelet agents and 
anticoagulant treatment at follow-up showed no statistically significant 
association (p = >0.05) between the variables and poor vascular outcome 
at follow-up, (Table 4.50).
4.4.7 Analysis of outcome: Poor vascular outcomc
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Figure 4.3: Survival curve of whole stroke cohort from poor vascular outcome.
Kaplan-Meier analysis of survival without poor vascular outcome according to 
the presence or absence of valvular strands
VS: 0 = No ; 1 = Yes
- n o
* O-censored 
1-censored
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Figure 4.4: Kaplan-Meier survival curves from poor vascular outcome according
to the presence or absence of valvular strands
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Table 4.50: Univariate logistic regression analysis of poor vascular outcome of the whole stroke cohort
Variable B S.E Wald df Sig Odds ratio 95 % C.I for Odds ratio
Lower Upper
Valvular strands 0.37 0.80 0.22 1 0.642 1.45 0.30 6.96
Age - 0.00 0.02 0.00 1 0.969 1.00 0.97 1.04
Yong and old 0.10 0.56 0.04 1 0.852 1.11 0.37 3.32
Gender 1.42 0.78 3.32 1 0.068 4.15 0.90 19.20
Diastolic dysfunction -0.38 0.80 0.23 1 0.633 0.68 0.14 3.29
Aortic valve abnormality 1.48 1.11 1.79 1 0.181 4.39 0.50 38.40
Mitral valve abnormality 0.09 0.88 0.01 1 0.918 1.10 0.20 6.13
Atrial fibrillation -1.75 1.30 1.82 1 0.177 0.17 0.01 2.21
Antiplatelet agents -0.37 1.08 0.12 1 0.729 0.69 0.08 5.71
Anticoagulants 0.18 0.67 0.07 1 0.787 1.20 0.32 4.43
B Intercept (the coefficient fo r the constant in the null model), S.E. Standard error around the coefficient fo r the constant, Wald Wald Chi-square test, d f  degrees o f
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
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There were a total of 17 events which met the end point poor combined 
outcome in the whole stroke cohort. The survival curve of the whole 
stroke cohort from poor combined outcome is shown in Figure: 4.5. The 
mean survival time was 772.34 days (Std. Error 27.02, 95% Cl: 719.36 - 
825.31). Kaplan-Meier survival curves in stroke cohort with or without 
VS from poor combined outcome were the same as the survival curves 
obtained for poor vascular outcome as the number of events were same 
in both. The log rank (Mantel-cox) test showed, %2 (1) = 0.49, p  = 0.483, 
(Figure 4.6).
Univariate logistic regression analysis of VS, age, gender, some TOE 
findings and antiplatelet and anticoagulant treatments showed no 
statistically significant association (p = >0.05) between the variables and 
poor combined outcome, (Table 4.51). Further application of a Cox 
proportional hazard model showed that there was no significant 
difference in the survival between those patients with or without VS. 
Total of cases = 78, total number of events (either poor vascular outcome 
or poor combined outcome) = 8, (Table 4.52). The relative risk is 1.66 
for developing a poor vascular outcome or poor combined outcome for 
cases with VS on TOE but p = 0.488 and the 95% Cl for odds ratio 
includes 1. A multivariate Cox proportional hazard model including 
gender and aortic valve abnormalities, the relative risk of poor vascular 
outcome or poor combined outcome was 0.31 (95% Cl 0.07- 1.44, p =
0.135) and both curves seem to meet after 400 days similar to the above 
model, (Table 4.53).
4.4.8 Analysis of outcome: Poor combined outcome
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Figure 4.5: Survival curve of whole stroke cohort from poor combined outcome
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Figure 4.6: Survival curves from poor vascular outcome based on valvular strand
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Table 4.51: Univariate logistic regression analysis of poor combined outcome of the whole stroke cohort
Variable B S.E Wald df Sig Odds ratio 95 % C.I for Odds ratio
Lower Upper
Valvular strands 0.63 0.77 0.66 1 0.416 1.87 0.41 8.43
Age 0.00 0.02 0.04 1 0.836 1.00 0.97 1.04
Yong and old 0.24 0.51 0.21 1 0.646 1.26 0.46 3.45
Gender 0.80 0.60 1.79 1 0.182 0.69 7.11 19.20
Diastolic dysfunction -0.72 0.75 0.90 1 0.342 0.49 0.11 2.14
Aortic valve abnormality 1.66 1.10 2.29 1 0.130 5.25 0.61 44.99
Mitral valve abnormality - 0.11 0.86 0.02 1 0.897 0.90 0.17 4.82
Atrial fibrillation -1.58 1.29 1.51 1 0.220 0.21 0.02 2.57
Antiplatelet agents -0.37 1.08 0.12 1 0.729 0.69 0.08 5.71
Anticoagulants 0.18 0.67 0.07 1 0.787 1.20 0.32 4.43
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f  degrees o f
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
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Table 4.52: Cox proportional hazard model based on presence or absence of VS
Variable B S.E Wald df Sig Odds ratio 95 % C.I for Odds ratio
Lower Upper
Valvular strands 0.51 0.73 0.48 1 0.488 1.66 0.40 6.99
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f degrees o f 
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
Table 4.53: Cox proportional hazard model including valvular strands, gender and aortic valve abnormalities
Variable B S.E Wald df Sig Odds ratio 95 % C.I for Odds ratio
Lower Upper
Valvular strands -1.18 0.79 2.24 1 0.135 0.31 0.07 1.44
Gender 1.17 0.88 1.79 1 0.181 3.22 0.58 17.90
Aortic valve abnormality 2.38 1.14 4.40 1 0.036 10.83 1.17 100.35
B Intercept (the coefficient for the constant in the null model), S.E. Standard error around the coefficient for the constant, Wald Wald Chi-square test, d f  degrees o f
freedom for the Wald Chi-square test, Sig. P-value, Exp(B) Exponentiation o f the B coefficient, which is an Odds ratio
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Chapter 5: Discussion
5.1Case-control study
In our single-centre case-control study, TOE-defined VS were found in 
approximately half of the patients with acute ischaemic stroke (AIS) and one third 
of controls. The analysis of our data showed an association between VS and risk of 
AIS (OR = 3.85,p  = 0.05). When adjusted for possible confounders, we found that 
those with VS were twice likely to have had an acute ischaemic stroke (OR = 2.15, 
p  = 0.06), but this finding did not reach statistical significance.
The prevalence of TOE-defined VS (48.7%) in patients with AIS in our study is at 
the high end of the range in the available published data (ranges from 6.3% to 47%o) 
(27). As the indication for TOEs were not blinded, a search for all possible cardiac 
sources of embolism might have contributed to increased detection of VS compared 
to previous studies. Valvular strands were found more frequently in older patients 
(61.8%>) compared to the young (38.6%o). Although this finding is in contrast to two 
previous studies (16, 27), a higher percentage (53%>) has been previously reported 
by Menzel et al. (28). The presence of VS in one-third of controls (32.6%>) was also 
higher than in two previous case-control studies (2.3%> to 16%) (15, 27), but a 
similar higher frequency (38%>) has been reported in normal subjects by Roldan et 
al. (29). The normal subjects in the later study were young with a mean age of 
35years (SD = 8) but the prevalence of VS matches to our controls (with a mean age 
of 63 years, SD = 15.4). As the method of selection of cases and controls was 
different to some of the previous studies, the difference in the prevalence of VS in 
cases and controls could be attributed to that as well.
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The association between TOE-defined VS and ischaemic stroke was previously 
demonstrated (OR 2.1, 95 % Cl 1.3-3.6;p  = 0.05) in a case-control study with 
similar study design to ours and the subjects were recruited prospectively after their 
index stroke and controls from patients underwent TOE for cardiac conditions (20). 
While the latter study was focussed only on mitral valve strands in the elderly, our 
study included VS on both mitral and aortic valve location in all the age groups. 
Although we were able to demonstrate a significant association (OR 3.85 p  = 0.05) 
between VS and AIS in our case-control study, the adjusted odds ratio was 2.15 
with a significance level of 0.06 in the two-level logistic backward stepwise 
(conditional) regression analysis. We believe that there is a significant association as 
described in previous studies (15, 16, 20, 27) even though, thep  valve is slightly 
>0.05. As the majority of our controls either had an established or a suspected 
cardiac disease, they would be at higher risk of having a cardiac source of emboli. 
Thus our control group would not be the ideal group of controls to compare the 
frequency of VS (a possible cardiac source of embolism, at least theoretically) 
versus stroke patients. Although we have adjusted for all known possible 
confounding variables, the lack of knowledge of vascular risk factors and the lack of 
follow-up for poor vascular outcome in controls might have reduced the significance 
level {p = <0.05) slightly in our multivariate logistic regression model compared to 
previous studies (20).
An association between mitral and aortic VS with VS was demonstrated 
independently with an Odds ratio of 3.5 and 3.7 respectively (with an overall Odds 
ratio of 4.4) by Roberts et al. (27) in patients referred for TOE for both stroke and 
other conditions. Although there was a strong association (OR 10.08, = 0.001)
between mitral VS and stroke demonstrated, the lack of association between aortic
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VS and stroke (OR 0.00, p  = 1.00) in our study supports the possible aetiology of a 
long term change in the cardiac valves for the development of VS (30) at least in the 
aortic location. This was also supported by the increased frequency of aortic 
valvular strands in our controls.
Mitral valve was the most common location for VS (60.5%) in cases similar to 
previous studies. The high prevalence of VS on the aortic valve (53.6%) in our 
controls was not observed before and perhaps this is due to our controls being older. 
Majority of mitral valves with VS (21/29; 72.4%) in our study were thickened. 
Nighoghossian et al. (30) and Freedberg et al. (15) identified valve thickening in 
10.5%) (4/38) and 8 %> (7/89) in all cardiac valves with VS respectively. This 
difference in the above studies may be explained by the methodological difference 
in the assessment of the valves in TOEs.
When the strokes were subtyped according to TOAST criteria (63), we have found 
similar prevalence of VS in both patients with an identified stroke mechanism 
(26/54; 48.1%o) and those without a determined mechanism (12/24; 50%>) after 
extensive stroke work-up. Our finding is at the upper limit of the previously 
reported prevalence of VS (15- 50%>) (16, 20, 27, 31) in cryptogenic stroke. VS 
were present in half of the patients with other identified cardioembolic sources 
(16/29; 55.2%o) and this is higher compared to previously reported (25-35%o) 
frequency of VS in cardioembolic stroke. We attribute the wide range of prevalence 
of VS in cardioembolic group due to the difference in the stroke subtyping used and 
the different ways of reporting in the studies that have investigated this topic. Some 
studies after subtyping the stroke mechanism reported the prevalence of VS in each 
while others identified patients with VS and reported the stroke aetiology of those 
patients. In the category of undetermined mechanism of stroke, the prevalence of VS
in cases with negative evaluation (7/15; 46.7%) was similar to cases with an 
incomplete evaluation (4/7; 57.1 %o).
It has been reported that VS are associated with systemic embolization (15) and to 
represent another risk factor for embolic cerebral ischaemia (16). Although 
cardioembolic stroke subtype in our study was found to have more VS (42.1 %>), we 
did not find any statistically significant association between VS and cardioembolic 
stroke (p = 0.52). Thus the association between VS and ischaemic stroke does not 
necessarily mean that VS are an actual embolic source as suggested by Roberts et al. 
(27). The prevalence of VS in cryptogenic (31.6%>) versus non-cryptogenic stroke 
(30%o) are same and there is no statistically significant association between VS and 
cryptogenic stroke (p=  1.00).
On neuroimaging of cases, the infarcts were found most commonly in subcortical 
areas. There was no statistically significant association between any infarct location 
(subcortical, cortical, cerebellar and brain stem) and the presence of VS. The 
findings were similar in cases with cryptogenic stroke on subsequent analysis and 
raises suspicion of embolic potential of VS further. There was no association 
between the severity of white matter changes and the presence of VS in our study.
The most common medium-risk cardiac sources of emboli in our cases were atrial 
sepal aneurysm and PFO with R-L shunt but the proportion of cases with or without 
VS and the above findings were comparable. When all individual medium-risk 
factors were analysed, hypokinesis of the left ventricle was found to be associated 
with VS (P value = 0.02) and the reason for this association is unclear. Although 
there were more cases with aortic plaques (grade 2, 3 and 4) and VS in cases and 
controls, it did not reach a statistical significance on analysis. The number of cases
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association between any of the high-risk factors and VS.
Diastolic dysfunction is a preclinical heart disease most commonly found in people 
with hypertension or advanced age. While half of our cases without VS had diastolic 
dysfunction on TOE, only one fifth of cases with VS did not have diastolic 
dysfunction. The strong association between diastolic dysfunction and valvular 
strands in case-control study has not been observed previously, to our knowledge.
We were unable to demonstrate any association between the presence of VS and 
hypercoagulable states by laboratory testing in young strokes. This could be due to 
small number of patients (9/43) with abnormalities which may be relevant in 
ischaemic stroke (69-71). This finding does not support the thrombotic origin of VS 
similar to one previous study (29) which investigated this topic.
with high-risk sources of emboli was small and we were unable to find any
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In our study, approximately one in 10 patients of the whole cohort had a poor 
vascular outcome (16/168; 9.5%) during the follow-up period. This poor vascular 
outcome rate is less than the rate of vascular outcome (stroke and death) reported in 
PICSS (31) study. The difference in the rate this could have been due to inclusion of 
only cryptogenic stroke, large numbers and longer period of follow- up in PICCS 
study. The majority of the cases were followed-up in a dedicated ‘stroke follow-up 
clinic’ in our centre which was in addition to the study follow-up. The reduced rate 
of poor vascular outcome could have been due to the implementation of the best 
secondary preventive treatment with antiplatelet therapy (86.3%>), anticoagulant 
therapy (36%>), improved blood pressure control and lifestyle modification (smoking 
cessation, reduced salt and alcohol intake, weight reduction etc.) after the primary 
stroke event.
There was no difference noted in the survival without poor vascular outcome of 
stroke patients with or without VS in our study. Our finding is consistent with the 
previous report by Cohen et al. (20) but we acknowledge similar limitations to their 
study such as lack of follow-up of controls for poor vascular outcome and a smaller 
number of primary outcome events. A relatively shorter follow-up period in our 
study might also have reduced our ability to detect any increased rate of poor 
vascular outcome in cases with VS. We were unable to fit a logistic regression 
model (Cox proportional hazard model) to our data, probably because of the small 
number of outcomes.
5.2Follow-up study
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The association of VS with AIS may not be cause and effect relationship due to the 
absence of increased prevalence of VS in cardioembolic stroke or cryptogenic stroke 
subtypes compared to controls. In addition, the lack of increased number of poor 
vascular outcome in cases with VS also queries the previously reported theory of VS 
being an embolic cause (15, 24, 56). The management of stroke was unaffected by 
the presence or absence of VS and the secondary prevention after the index stroke is 
unlikely to reduce the number of poor vascular outcome in our cases with VS
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5.3Limitations
Most of the recruited patients had a milder stroke (only 19.5% had NIHSS >6). A 
number of factors could have contributed, including time of assessment for 
recruitment (median 7 days) and difficulty obtaining consent from family members 
allowing patients with more severe, debilitating stroke to undergo TOE. While all 
cases with ‘stroke of undetermined aetiology- negative evaluation’ underwent TOE, 
only one fourth of cases with a stroke mechanism of large artery disease underwent 
TOE. This should not affect our ability to understand the overall prevalence of VS 
in the stroke cohort as we believe that the cases in the case-control study were 
representative of the whole stroke cohort of patients. The indication for TOE in 
cases was not blinded and the analysis of the TOEs was done by a single 
experienced Consultant Cardiologist and not by a panel of observers.
Although we were able to follow-up majority of cases in clinics, we had to perform 
telephonic interview and chart review in a minority those who did not attend the 
clinic. In those 5%, the information about vascular risk factor control and stroke 
recovery was limited and less reliable. TOEs were repeated only for 8 patients and 
we did not have sufficient resources to ensure repeat TOEs in our study participants. 
Other studies have reviewed the natural course of VS (29, 30) and the clinical 
outcome of cases with VS on antiplatelet agent versus anticoagulant treatment (31). 
We do not believe that we could have contributed any other major findings and 
would not have been cost effective in repeating TOEs for all the participants. The 
reduced number of poor vascular outcome in cases with VS may be due to a 
relatively shorter follow-up period in our study.
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When multiple statistical tests are performed, some fraction will be false positives 
(72). There were no corrections made for multiple comparisons in our study and we 
acknowledge that there is a random chance of misinterpretation of the results (i.e. 
false positive or type 1 error). There was no matching done between cases and 
controls and we acknowledge that this is a deficiency of our study. In the future, this 
difficulty may be overcome by collecting the data on vascular risk factors at the time 
of TOE using a face-to-face interview or by asking patients to till in a short 
questionnaire, which can be subsequently verified by examining medical notes if 
necessary.
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5.4Strengths
All the cases were recruited prospectively in our study after a detailed neurological 
examination and had extensive investigations to determine their stroke mechanism. 
Although, the patient population in case-control study may seem relatively limited 
(due to the difficulty in obtaining TOE for all cases), the sample size of the patients 
included in the analysis (78 cases and 89 controls) was more than sufficient to 
achieve the primary aim of the case-control study (2.2.a) and to ensure sufficient 
power (>80%) of the results according to our a priori sample size computations.
In the case-control study, there were only 7 patients in the group of cryptogenic 
stroke with incomplete investigation. All the patients were recruited prior to the 
finding of interest identified by investigation. All the neuroimaging was reviewed 
by an experienced Consultant Neurologist and Consultant Neuroradiologists. The 
stroke subtyping based on clinical findings and investigations was performed by a 
Neurologist with special expertise in stroke. The majority of TOEs were performed 
by an experienced Cardiologist. The association between other possible cardiac 
sources of emboli and VS was investigated thoroughly. We were able to investigate 
infarct topography in patients with VS which had not been studied previously. A 
hypercoagulable state had been tested for the majority of young cases to investigate 
the possibility VS being thrombotic in origin and their association with other 
hypercoagulable states in patients with stroke.
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5.5 Future direction
Valvular strands identified by TOE performed following stroke could have 
developed any time prior to the index stroke. Although an association has been 
identified between VS and stroke we were unable to identify a ‘cause- effect’ 
relationship from our study. VS were not significantly more frequent in 
cardioembolic and cryptogenic stroke subtype in our study, suggesting that VS were 
less likely to be an embolic risk factor (15, 16). There could be an unrecognised 
common factor to initiate the development of risk factors for stroke as well as for 
VS. There is a possibility of overestimating the prevalence of VS in a group of 
controls identified from those who underwent TOE for evaluating suspected or 
existing cardiac disease. To address the above, all participants of the study should be 
identified from healthy subjects of all age groups and all should undergo TOE. 
Subjects with VS (the possible risk factor) and without VS (without risk factor) 
should be followed up for longer periods than previously studied in order to capture 
vascular events (including stroke). Thus the true prevalence of VS can be estimated 
and the rate of vascular events/ stroke can be calculated in those with or without VS. 
Such a study would involve extensive resources and could not be undertaken unless 
it is a part of a large epidemiological study. Without establishing a ‘cause-effect’, 
the indication of TOE for identification of a possible risk factor (VS) for stroke 
cannot be recommended currently without the absence of any other cardiac disease. 
Unless there is a high risk of causing recurrent embolic stroke (similar to atrial 
fibrillation), the management of acute ischaemic stroke with antiplatelet therapy is 
unlikely to change irrespective whether they have VS or not.
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5.6 Conclusion
Valvular strands were found in half of the patients with A1S compared to one third 
of controls. Similar to previous studies, we found an association between TOE- 
defined VS and acute ischaemic stroke, however, the strength of the association was 
reduced in multivariate analysis. We showed a statistically significant association 
between diastolic dysfunction and VS in case-control study. Due to lack of 
increased frequency of VS in cardioembolic and cryptogenic stroke subtype and 
absence of increased risk of recurrent stroke in patients with VS versus those 
without, the causal relationship of VS to stroke as an embolic risk factor is unlikely.
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Study Title: A prospective study of trans-oesophageal echocardiogram (TOE) 
defined valvular strands in a hospital cohort with acute ischaemic stroke
Principal Investigator’s Name: Joan Moroney
Principal Investigator’s Title: Dr
Telephone No. of Principal Investigator: 01 809 2258
You are being invited to take part in a clinical research study carried out at Beaumont 
Hospital. Before you decide whether or not you wish to take part, you should read the 
information provided below carefully and if you wish discuss it with your family, 
friends or GP. Take time to ask questions -  do not feel rushed or under any obligation 
to make a hasty judgement. You should clearly understand the risks and benefits of 
participating in this study so that you can make a decision that is right for you -  this 
process is known as Informed Consent.
You are not obliged to take part in this study and failure to participate will have no 
effect on your future care.
You may change your mind at any time (before the start of the study or even after you 
have commenced the study) for whatever reason without having to justify your decision 
and without any negative impact on the care you will receive from the medical staff. 
Why is this study being done?
You are undergoing investigation and management of what is called an “ischaemic 
stroke.” Ischaemic stroke means stroke caused by a lack of blood supply to certain areas
Appendices
Appendix 1 Patient Information Leaflet
134
of brain normally due to a clot. Abnormalities on a heart scan can be seen in some 
individuals with stroke. The aim of this study is to increase our understanding of one 
such abnormality called “valvular strands” (strands on heart valves). In general as a part 
of routine stroke work up, some individuals might undergo a special heart scan called 
transoesophageal echocardiogram (TOE). It is done by putting a small camera down 
through the food pipe and then taking pictures of chambers and valves of the heart. In 
people with certain abnormalities in the scan the current practice by cardiologists is to 
repeat the scan in 6 months.
Who is organising and funding this study?
No funding is organised for this study.
How will it be carried out?
We plan to include patients presenting to Beaumont Hospital with stroke over a fixed 
period. These patients will be approached by Dr Albi Chalissery, one of the doctors 
involved in conducting this study.
What will happen to me if I agree to take part?
If you agree to participate in the study, a doctor from the research team will take a 
detailed history of your present condition and other medical problems. He or she will 
examine you on a few occasions during your hospital stay. Our study will not affect the 
decisions regarding the choice of tests made by your doctors. We will analyse all the 
results of the blood tests, x rays and scans you undergo as a part of your treatment. You 
will be required to attend our follow- up clinic 6 months after your hospital discharge. 
During this visit you will be fully examined by a qualified doctor.
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Benefits
There is no immediate benefit. But the information received will be analysed after the 
completion of study and this will increase the knowledge and understanding of the 
causes of stroke.
Risks
There are no risks associated with your participation in this study. There are no painful 
procedures.
Confidentiality issues
Your general practitioner will be notified by a letter stating that you are participating in 
the research. Your medical notes will be examined by the investigators. The details 
collected will be coded to protect your identity. This data will be stored in paper form 
and digitally in Beaumont Hospital. The data in the paper form will be kept in a locked 
office in Beaumont Hospital; access will be available only to the research team. Digital 
access will require passwords which are known only to the investigators. At the end of 
the study the coded data will be analysed by a statistician. All data will be destroyed 
after two years of completing the study.
The final results will be submitted in the form of a thesis for the degree of Doctorate of 
Medicine (MD) for one of the co-investigators (Dr. Albi Chalissery)
If you have any further questions about the study or if you wish to withdraw from the 
study you may do so without justifying your decision and your future treatment will not 
be effected.
For additional information now or any future time please contact:
Name: Dr Joan Moroney
Address: Consultant Neurologist, Beaumont Hospital, Dublin., Phone No: 01 809 2258
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Appendix 2 Information Leaflet for Next of Kin/ Relatives
Study Title: A prospective study of transoesophageal echocardiogram (TOE) 
defined valvular strands in a hospital cohort with acute ischaemic stroke.
Principal Investigator’s Name: Joan Moroney
Principal Investigator’s Title: Dr
Telephone No. of Principal Investigator: 01 809 2258
Your relative is invited to take part in a clinical research study carried out at Beaumont 
Hospital. Before you decide whether or not you wish he/she to take part, you should 
read the information provided below carefully and if you wish discuss it with your 
family, friends or GP. Take time to ask questions -  do not feel rushed or under any 
obligation to make a hasty judgement. You should clearly understand the risks and 
benefits of him/her participating in this study so that you can make a decision that is 
right for your relative.
Your relative is not obliged to take part in this study and failure to participate will have 
no effect on his/her future care.
You may change your mind at any time (before the start of the study or even after 
he/she have commenced the study) for whatever reason without having to justify your 
decision and without any negative impact on the care your relative will receive from the 
medical staff.
Why is this study being done?
Your relative is undergoing investigation and management of what is called an 
“ischaemic stroke.” Ischaemic stroke means stroke caused by a lack of blood supply to 
certain areas of brain normally as a result of a clot. Abnormalities on a heart scan can be
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seen in some individuals with stroke. The aim of this study is to increase our 
understanding of one such abnormality called “valvular strands” (strands on heart 
valves). Some individuals might undergo a special heart scan called transoesophageal 
echocardiogram (TOE) as apart of their routine stroke workup to find out the cause of 
stroke. It is done by putting a small camera down through the food pipe and then taking 
pictures of chambers and valves of the heart. In people with certain abnormalities in the 
scan the current practice by cardiologists is to repeat the scan in 6 months.
Who is organising and funding this study?
No funding is organised for this study. The final results will be submitted in the form of 
a thesis for the degree of Doctorate of Medicine (MD) for one of the co-investigators 
(Dr. Albi Chalissery)
How will it be carried out?
We plan to include patients presenting to Beaumont Hospital with stroke over a fixed 
period. These patients will be approached by Dr Albi Chalissery, one of the doctors 
involved in conducting this study.
What will happen to your relative if you agree to take part?
If your relative agrees to participate in the study, a doctor from the research team will 
take a detailed history of his/her present condition and other medical problems. He or 
she will be examined on a few occasions during your hospital stay. Our study will not 
affect the decisions regarding the choice of tests made by his/her doctors. We will 
analyse all the results of the blood tests, X rays and scans he/she undergo as a part of the 
treatment. He/she will be required to attend our follow- up clinic 6 months after the 
discharge from the hospital. During this visit he/she will be fully examined by a 
qualified doctor.
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Benefits
There is no immediate benefit. But the information received will be analysed after the 
completion of study and this will increase the knowledge and understanding of the 
causes of stroke.
Risks
There are no risks associated with the participation in this study. There are no painful 
procedures.
Confidentiality issues
His/her general practitioner will be notified by a letter stating that he/she is participating 
in the research. The medical notes will be examined by the investigators. The details 
collected will be coded to protect his/her identity. This data will be stored in paper form 
and digitally in Beaumont Hospital. The data in the paper form will be kept in a locked 
office in Beaumont Hospital; access will be available only to the research team. Digital 
access will require passwords which are known only to the investigators. At the end of 
the study the coded data will be analysed by a statistician. All data will be destroyed 
after two years of completing the study.
The final results will be submitted in the form of a thesis for the degree of Doctorate of 
Medicine (MD) for one of the co-investigators (Dr. Albi Chalissery)
If you have any further questions about the study or if you wish to withdraw your 
relative from the study you may do so without justifying your decision and his/her 
future treatment will not be effected.
For additional information now or any future time please contact:
Name: Dr Joan Moroney
Address: Consultant Neurologist, Beaumont Hospital, Dublin., Phone No: 01 809 2258
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Study Title: A prospective study of transoesophageal echocardiogram (TOE) 
defined valvular strands in a hospital cohort with acute ischemic stroke.
Please tick the appropriate answer:
I confirm that I have read and understood the Patient Information Leaflet dated_____
attached, and that I have had ample opportunity to ask questions all of which have been 
satisfactorily answered.
□ Yes DNo
I understand that my participation in this study is entirely voluntary and that I may 
withdraw at any time, without giving reason, and without this decision affecting my 
future treatment or medical care.
□ Yes DNo
I understand that my medical notes may be viewed by investigators in the research 
study
□ Yes DNo
I understand that my identity will remain confidential at all times.
□ Yes DNo
I am aware of the potential risks of this research study.
□ Yes DNo
I have been given a copy of the Patient Information Leaflet and this Consent form for 
my records.
□Yes DNo
Appendix 3 Consent form
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I agree that I will not restrict the use to which the results of this study may be put. I give 
my approval that unidentifiable data concerning my person may be stored or 
electronically processed for the purpose of scientific research and may be used in 
related or other studies in the future. (This would be subject to approval by an 
independent body, which safeguards the welfare and rights of people in biomedical 
research studies - the Beaumont Hospital Ethics (Medical Research) Committee.)
□ Yes □No
Patient________________ _____________________
Signature and dated Name in block capitals
To be completed by the Principal Investigator or his nominee.
I the undersigned have taken the time to fully explain to the above patient the nature and 
purpose of this study in a manner that he/she could understand. I have explained the 
risks involved, as well as the possible benefits and have invited him/her to ask questions 
on any aspect of the study that concerned them.
Future use of coded data:
Signature: Name in Block Capitals: Qualification: Date:
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Study Title: A prospective study of transoesophageal echocardiogram (TOE) 
defined valvular strands in a hospital cohort with acute ischemic stroke.
Please tick the appropriate answer:
I confirm that I have read and understood the Information Leaflet for Next of
Kin/Relatives dated ___ attached, and that I have had ample opportunity to ask
questions all of which have been satisfactorily answered.
□ Yes DNo
I understand that participation of my relative in this study is entirely voluntary and that 
he/she may withdraw their participation at any time, without giving reason, and without 
this decision affecting his/her future treatment or medical care.
□ Yes DNo
I understand that his/her medical notes may be viewed by investigators in the research 
study
□ Yes QNo
I understand that his/her identity will remain confidential at all times. □ Yes DNo
I am aware of the potential risks of this research study.
□ Yes DNo
I have been given a copy of the Information Leaflet for Next of Kin/Relatives and this 
Assent form for my records.
□ Yes QNo
Future use of coded data:
I agree that I will not restrict the use to which the results of this study may be put. I give 
my approval that unidentifiable data concerning my relative may be stored or
Appendix 4 Assent form
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electronically processed for the purpose of scientific research and may be used in 
related or other studies in the future. (This would be subject to approval by an 
independent body, which safeguards the welfare and rights of people in biomedical 
research studies - the Beaumont Hospital Ethics (Medical Research) Committee.)
□ Yes DNo
Patient’ s name __________________
Next of Kin/Relative’s ____________________________________
Signature and dated Name in block capitals
To be completed by the Principal Investigator or his nominee.
1 the undersigned have taken the time to fully explain to the above patient’s next of 
kin/relative the nature and purpose of this study in a manner that he/she could 
understand. I have explained the risks involved, as well as the possible benefits and 
have invited him/her to ask questions on any aspect of the study that concerned them.
Signature: Name in Block Capitals: Qualification: Date:
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I.a. Level of Consciousness:
0 Alerts
1 Not alert, but arousable with minimal stimulation
2 Not alert, requires repeated stimulation to attend
3 Comma
l.b. Ask patient the month and their age:
0 Answers both correctly
1 Answers one correctly
2 Both incorrect
1.e. Ask patient to open and close eyes:
0 Answers both correctly
1 Answers one correctly
2 Both incorrect
2. Best Gaze (only horizontal eye movement):
0 Normal
1 Partial gaze palsy
2 Forced deviation
3. Visual Field Testing:
0 No visual field loss
1 Partial hemianopia
2 Complete hemianopia
3 Bilateral hemianopia (blind including cortical blindness)
Appendix 5 Stroke and Brain Attack - NIH Stroke Scale
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4. Facial Paresis (Ask patient to show symmetrical movement teeth 
or raise eyebrows and close eyes tightly):
0 Normal
1 Minor paralysis (flattened nasolabial fold, asymmetry on smiling)
2 Partial paralysis (total or near total paralysis of lower face)
3 Complete paralysis of one or both sides (absence of facial movement in the upper and 
lower face)
5. Motor Function - Arm (right and left): (extends arms 90 (or 45) degrees for 10 
seconds without drift)
0 Normal
1 Drift
2 Some effort against gravity
3 No effort against gravity
4 No movement
9 Untestable (Joint fused or limb amputated)
6. Motor Function - Leg (right and left): (hold leg 30 degrees position for 5
seconds)
0 Normal
1 Drift
2 Some effort against gravity
3 No effort against gravity
4 No movement
9 Untestable (Joint fused or limb amputated)
7. Limb Ataxia:
0 No ataxia
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1 Present in one limb
2 Present in two limbs
8. Sensory (Use pinprick to test arms, legs, trunk and face -- compare side to side
0 Normal
1 Mild to moderate decrease in sensation
2 Severe to total sensory loss
9. Best Language (describe picture, name items, read sentences)
0 No aphasia
1 Mild to moderate aphasia
2 Severe aphasia
3 Mute
10. Dysarthria (read several words):
0 Normal articulation
1 Mild to moderate slurring of words
2 Near unintelligible or unable to speak
9 Intubated or other physical barrier
11. Extinction and Inattention:
0 Normal
1 Inattention or extinction to bilateral simultaneous stimulation in one of the sensory 
modalities
2 Severe hemi-inattention or hemi-inattention to more than one modality
146
Appendix 6 Barthel Index
Activity Score:
Feeding
0 = unable
5 = needs help cutting, spreading butter, etc., or requires modified diet
10 = independent______
Bathing 
0 = dependent
5 = independent (or in shower)______
Grooming
0 = needs to help with personal care
5 = independent face/hair/teeth/shaving (implements provided)_____
Dressing 
0 = dependent
5 = needs help but can do about half unaided
10 = independent (including buttons, zips, laces, etc.)______
Bowels
0 = incontinent (or needs to be given enemas)
5 = occasional accident
10 = continent _ ____ _
Bladder
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent______
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0 = dependent
5 = needs some help, but can do something alone
10 = independent (on and off, dressing, wiping)______
Transfers (Bed to chair and back)
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit
10 = minor help (verbal or physical)
15 = independent______
Mobility (on level surfaces)
0 = immobile or < 50 yards
5 = wheelchair independent, including corners, > 50 yards
10 = walks with help of one person (verbal or physical) > 50 yards
15 = independent (but may use any aid; for example, stick) > 50 yards
Stairs
0 = unable
5 = needs help (verbal, physical, carrying aid)
10 = independent______
Toilet use
Total (0-100):
Provided by the Internet Stroke Center www.strokecenter.org
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a) In a fairly large ease-control study conducted between 1991 and 1993, Freedberg 
et al. (15) noted that VS were found in 5.5% (86/1559) of patients undergoing 
TOE. Of the 597 patients with an embolic event (included stroke, TIA and 
peripheral emboli), 10.6%o (63/597) had VS, compared with only 2.3% (23/962) 
of patients without an embolic event (odds ratio 4.8, 95% confidence interval 
[Cl] 3.0 to 7.9, p  = 0.0001).
b) In 1996 Tice et al. (16) evaluated mitral valves in 968 patients referred for TOE 
over a period of two years and mitral VS were identified in 2.3% (22/968). VS 
were present in 6.3%> (20/318) of patients who had a recent ischaemic 
cerebrovascular event compared with 0.3%> (2/650) patients studied for other 
indications (p < 0.00001).
c) In 1997, Roberts et al. (27) selected 73 cases and controls from a group of 453 
consecutive patients referred for TOE over a 9-month period. He reported a VS 
frequency of 47%) (34/73) in the group of patients undergoing TOE for 
indications of ischaemic stroke or TIA and a frequency of 16 % (12/73) in the 
control group undergoing TOE for indications other than stroke or TIA.
d) In a case-control study by Cohen et al. (20) published in 1997, mitral VS were 
reported in 22.5% (64/284) of cases selected from 385 patients older than 60 
years consecutively admitted to neurology departments for brain infarction 
(information on VS was missing in 51 cases). Mitral VS were found in 12.1 % 
(31/256) of control subjects with no history of brain embolisation or peripheral 
embolisation. Controls included patients with endocarditis, intracavitary masses, 
suspicion of aortic dissection, pulmonary embolism and inadequate TTE.
Appendix 7 Prevalence of valvular strands from previous studies
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e) In 1997 Menzel et al. (28) in a prospective study, examined prevalence and 
echocardiographic characteristics of VS on native aortic valves. He found VS in 
39% (86/218) of patients who had undergone TOE for several indications 
excluding endocarditis, severe calcification of aortic cusps or aortic valve ring. 
The prevalence was 46%> in patients with a recent history of embolism who had 
undergone TOE compared to 34%> prevalence without such a history.
f) In 1997, Roldan et al. (29) prospectively studied the prevalence, evolution and 
embolic risk of VS in normal subjects and patients aged < 60 years with and 
without suspected cardioembolism. This study showed a similar prevalence of 
VS in normal subjects (38%>; 34/90) and in patients with (41%>; 20/49) or 
without (47%>; 41/88) suspected cardioembolism regardless of age and gender.
g) In 1998, Nighoghossian et al. (30) estimated changes in the VS in patients who 
were referred for TOE for stroke or cardiac pathology through a serial TOE 
study. This study showed that 10% (34/340) patients had VS on any cardiac 
valves. Among 34 patients with VS, 18.8%) (30/340) were referred for stroke 
whereas 2.2% (4/340) were admitted with cardiac pathology.
h) More recently in 2004, Homma et al. (31) analyzed 619 TOE studies in stroke 
patients enrolled in the Patent Foramen Ovale in Cryptogenic Stroke Study 
(PICSS), a randomized study which investigated the rate of recurrent ischaemic 
stroke or death on aspirin or warfarin. VS were present in 39.4%> (244/619) of 
the study population.
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